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Overview  
 
This thesis was submitted as part of the Doctorate in Clinical Psychology at the School of 
Psychology, University of Birmingham. It comprises two volumes. The first volume is the 
research component and includes a review of the literature and an empirical study. The 
second volume is the clinical component and includes five clinical practice reports. 
 
Volume I: Research Component 
Motivational based approaches have been shown to be effective in reducing problematic 
behaviours such as alcohol and substance use in the general population. The present study 
reviewed 31 studies that aimed to reduce a number of problematic behaviours amongst 
individuals with severe mental health problems (that is, diagnoses of a psychotic illness or 
major affective / anxiety disorder). These studies were categorised as those that aimed to 
increase ‘healthy’ behaviours, either adherence to prescribed anti-psychotic medication or 
treatment attendance, and studies that aimed to decrease ‘unhealthy’ behaviours, 
specifically alcohol and substance use.  
 
It was concluded that the evidence supporting the efficacy of motivational based 
approaches in increasing adherence to medication was inconsistent. In the minority of 
studies where an increase in medication was reported, the duration of effect appeared to 
decline over time. Yet a number of studies tended to use lengthy outcome periods which 
were unlikely to have captured this short term increase in medication. The outcomes for 
the studies that aimed to increase treatment retention were more encouraging with the 
majority of studies reporting an increase in treatment attendance. Duration of outcome was 
typically brief, rarely measuring attendance beyond the first appointment. The evidence 
from the studies that aimed to reduce ‘unhealthy’ behaviours was much more consistent, 
with a greater proportion of studies that indicated a reduction in poly-drug use as well as 
reductions in specific substance such as alcohol, tobacco and amphetamine use, whereas 
the evidence for cannabis was less certain. There was evidence that when baseline levels of 
motivation were initially high, that other more directive interventions may be equally 
effective.  
 
A number of other positive outcomes from the motivational based approaches were 
reported, notably reductions in levels of dependence, general functioning and mental health 
 
symptomatology. The majority of studies that measured the duration of effect beyond the 
end of treatment reported that the effect appeared to decline over time. A number of 
methodological limitations require these results to be treated with caution, notably, small 
sample sizes and a lack of control for the additional therapist attention that resulted from 
the motivational based approach. It is the opinion that the evidence indicates that 
motivational based approaches are effective in reducing substance use and increasing 
treatment retention where baseline levels of motivation are low. It is likely that 
interventions would have to be ongoing in order to maintain effect. Where baseline levels 
of motivation are not low, other more directive interventions such as psycho-education 
may be equally effective. 
 
 
The empirical paper presents a quantitative study that aimed to look at the reasons for 
cannabis use amongst individuals with and without severe mental health problems. 
Participants were either cannabis users with a severe mental health illness or cannabis 
users without a severe mental illness. Participants were interviewed about their motivations 
for using cannabis and their expectations related to the effects of using cannabis. It was 
found that the motivations for using cannabis did not differ between the two groups; with 
individuals with severe mental health problems, and those without, both using cannabis to 
cope with negative affect, for pleasure and for social reasons. However, individuals with 
severe mental health problems differed in that they expected cannabis to be more ‘socially 
and sexually facilitative’. The finding from the qualitative component of the study 
indicated that only a small minority of individuals with severe mental health problems used 
cannabis to manage the symptoms of their illness or the side effects of medication. 
Irrespective of mental health status, participants who used cannabis more problematically 
endorsed more coping and pleasure motives. A number of recommendations are suggested 
for interventions to reduce the enhancement and coping related motivations amongst more 
problematic cannabis users with severe mental health problems. I suggest that interventions 
aimed at reducing sources of distress, supporting the development of more adaptive ways 
of coping, as well as treatments aimed at facilitating more adaptive ways of obtaining 
pleasure other than through cannabis use may be helpful.  
 
 
 
 
Volume II: Clinical Component 
The second volume of the thesis presents five clinical practice reports. Firstly, a case 
formulation from a schema focused and psychodynamic perspective are presented for a 
female with relationship difficulties and feelings of depression, referred to a community 
mental health team. Secondly, a single case experimental design that measured the efficacy 
of a cognitive behavioural therapy intervention in helping a woman with post-traumatic 
stress disorder access the community is reported. Thirdly, a case formulation and 
intervention from a cognitive behavioural perspective is presented for a boy with 
separation anxiety referred to a child and adolescent mental health service. Fourthly, an 
evaluation of a consent form designed to facilitate the consent process for users of a 
learning disability dementia assessment service is presented. Lastly an abstract is presented 
for a case study where psychodynamic psychotherapy was used with a man who presented 
with relationship difficulties and feelings of depression and anxiety within a tertiary care 
service.   
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Abstract 
 
 
Motivational based approaches have shown efficacy in reducing problematic behaviours 
amongst the general population. There are several difficulties frequently faced by people 
with severe mental health problems for which a change in behaviour is likely to lead to 
improved prognosis. Empirical studies (n=31) that explored the impact of motivational 
based approaches upon behaviour change amongst individuals with severe mental health 
problems were reviewed. The literature was categorised into interventions designed to 
reduce unhealthy behaviour (alcohol, substance use and smoking n= 18) and interventions 
aimed at increasing healthy behaviour (adherence to medication and treatment retention n= 
13). This review examined the clinical effectiveness of these motivational based 
approaches. A greater proportion of studies indicated a positive treatment effect for 
motivational based approaches. The evidence was more consistent for the studies that 
aimed to reduce substance use reporting efficacy amongst a range of substances, although 
the effect for cannabis was less certain. The few studies that aimed to increase treatment 
retention were positive. The evidence was less consistent for the studies that aimed to 
increase adherence to medication.  Behavioural change is reported amongst a wide range of 
severe mental health diagnoses, delivered in either groups or individual settings. Many of 
the studies measuring longer term outcomes reported a decline in effect over time. More 
directive interventions (e.g. advice or psycho-education), may be at least as effective when 
baseline levels of motivation are high, suggesting the use of a stepped care approach to 
intervention. Recommendations are provided for future research.  
 
 
 
 
 
 
 
 
 
  
Introduction 
 
 
The Psychology of Change 
National Health Service (NHS) users are frequently given advice or support in changing 
what are considered ‘unhealthy behaviours’, yet this advice has limited impact upon 
behaviour change, even when the negative consequences of such behaviour are apparent to 
the clinicians offering the advice (Tyrer & Weaver, 2004). Behavioural change is central to 
the field of Clinical Psychology and Clinical Psychologists are suitably equipped to 
examine the processes of change through the development of explanatory theories and 
models and the testing of these models via well designed and robust empirical research 
(Hall & Llewelyn, 2007). Tyrer and  Weaver, (2004) suggest these empirically proven 
theories can be then applied within the context of the NHS in order to overcome unhealthy, 
problematic and sometimes destructive behaviour amongst the users of the service.  
 
One model that been developed to understand why people change, or more importantly, do 
not change, and has received widespread empirical support is the Transtheoretical Model 
of Change (Prochaska & Norcross, 2001). This model suggests that the lack of behaviour 
change is not a sign of resistance or characterlogical problems, but represents an early 
stage of a behaviour change process. Change is conceptualized as a process that unfolds 
over time and involves progression through a series of six stages: pre-contemplation, 
contemplation, preparation, action, maintenance, and termination (Prochaska & 
DiClemente, 1992). In this model, effective collaboration best occurs when a therapist 
selects interventions that match the individual’s particular stage of change (Prochaska & 
Norcross, 2001).  
 
Motivational interviewing and its evidence base 
Motivational interviewing (Miller & Rollnick, 1991) is a method that utilises the concept 
of stages in the behavioural change process. It first gained empirical support when used to 
motivate substance users to change addictive substance use behaviours (Miller & Rollnick, 
2002) and has since gained empirical support amongst a wide range of problematic 
behaviours. See Hettema, Steele & Miller (2005) for a review.  
 
 Difficulties faced by individuals with Severe Mental Health problems 
The symptoms of schizophrenia can sometimes be treated by adherence to antipsychotic 
medication. Non-compliance to antipsychotic medication can be a cause of relapse (Gray, 
Wykes & Gournay, 2002). Despite this, medication non-adherence is estimated to be about 
50% (Nose, Barbui & Tansella, 2003). This can be understood in the context that 
medication is, by and large, unpleasant in its immediate effects but beneficial in the long 
term (Tyrer & Weaver, 2004).   
 
The adverse outcomes associated with schizophrenia and substance misuse are well 
documented (Johnson, Thornicroft, Afuwape, Leese, White, Hughes, Wanigaratne, Miles, 
& Craig, 2007). Approximately 50 percent of individuals with severe mental health 
problems will develop a substance use disorder at some point during their lives (Bellack, 
Bennett, Gearon, Brown & Yang, 2006) and approximately 25 percent will display current 
substance dependence or abuse (Rachbiesel, Scott and Dixon, 1999). This can be 
understood in the context that substance use is frequently perceived as pleasant in its 
immediate effects but may actually be damaging in the long term (Tyrer & Weaver, 2004). 
According to the transtheoretical model of change, poor adherence to such treatments 
represents an early stage of a behaviour change effort. The question that arises for 
psychological researchers is therefore ‘Can motivational based approaches, which have 
demonstrated efficacy in behaviour change amongst individuals without severe mental 
health problems, be applied to individuals with severe mental health problems, so that the 
factors associated with poor prognosis amongst this group can be better treated?’ This 
question forms the basis of the current review. 
 
There are reasons to believe that motivational based approaches may be applied 
successfully to individuals with severe mental health problems. Motivational based 
approaches adopt a non-confrontational approach. Individuals with severe mental health 
problems are less able to benefit from more confrontational approaches as direct challenges 
to delusional thinking are usually ineffective (Martino, Carroll, Kostas, Perkins & 
Rounsaville, 2002). Service users with severe mental health problems are often reluctant to 
engage with services and therefore only short intervention periods may be available. Due 
to their potential for brevity, motivational based approaches are considered well suited to 
working within a limited time frame (Van Horn & Bux, 2001). However, there are also 
 
factors that would suggest that motivational based approaches may not be applied 
successfully to individuals with severe mental health (SMH) problems. Bellack and 
DiClemente (1999) indentified three areas in which individuals with schizophrenia may 
experience specific difficulties that inhibit the change process. These areas are cognitive 
impairment, social impairment, and obstacles to motivation. Cognitive deficits are thought 
to be the most significant obstacle and include memory problems, attention deficits, 
difficulties in abstract thought, executive functioning difficulties as well as active positive 
symptoms. Consequently more simple and clear approaches may be required (Corrigan, 
McCracken and Holmes, 2001).   
  
Present Review 
The purpose of the present study was to systematically review available published 
interventions that incorporate motivational based approaches into an active intervention 
amongst samples from the SMH population in order to establish whether empirical studies 
reported a significant intervention effect. For the purpose of the present review, behaviours 
where motivational approaches have been applied will be categorised into either: i) 
motivational based interventions aimed at increasing positive behaviours, which include 
interventions to improve adherence to psychotropic medication and interventions to 
improve retention and engagement to treatment; and ii) motivational based interventions 
aimed at decreasing negative behaviours, which include alcohol use, non -prescribed drug 
misuse and tobacco use.  
 
Barkhof, Haan, Meijer, Fouwels, Keet, Hulstijn, Schippers and Linszen, (2006) adopted a 
narrative review of studies using motivational based approaches up to 2006, amongst 
individuals with schizophrenia and recommended that further research of these preliminary 
findings was required. The present study extends the work of Barkhof et al., (2006) by 
systematically reviewing studies utilising motivational approaches amongst all severe 
mental health problems, published up to February 2010.   
 
 
 
 
 
 
 
  
Method 
 
Search Strategy  
Terminology 
For the purpose of this review, “severe mental health” (SMH) problems refers to major 
mental illnesses such as those on the schizophrenia spectrum (schizophrenia, 
schizophreniform and schizoaffective disorder), bipolar disorder and major depression, 
when they are associated with prolonged disability. “Substance use disorders” refers to 
abuse, misuse or dependence on alcohol or other controlled drugs as well as nicotine. Dual 
diagnosis refers to co-occurring severe mental health problems and substance use 
disorders.  
 
Inclusion Criteria 
• Interventions containing a component of motivational interviewing 
• Samples consisting of participants with a diagnosis of SMH problems only  
• Studies published from 1991 to February 2010 
• In English language  
 
Procedure 
The following databases: CINAHL, PsycINFO, Ovid Medline and PubMED were searched 
for articles or books using the following search phrases:  
 
SMI or severe mental illness or SMH or severe mental health or schizo$ or bipolar 
or major depression or dual diagnosis or co-morbidity; AND motivational interviewing or 
MI or compliance therapy or CT or adherence therapy or AT or treatment adherence or 
treatment retention or engagement or stages of change or transtheoretical model of change.  
 
This search identified 48 journal articles, 28 were excluded as they did not fit the inclusion 
criteria. Further searching was undertaken by means a reference list/citation search of these 
studies which resulted in an additional 11 articles. The search was considered complete 
when no additional publications could be found. 
 
 Search Results 
31 studies met the inclusion criteria, and were further analysed and classified in descending 
order of robustness. Randomised Controlled Trials (RCTs) are considered a superior 
methodology in the hierarchy of evidence, because they limit the potential for bias by 
randomly assigning one patient pool to an intervention and another patient pool to non-
intervention (or placebo) which minimises the occurrence of confounding variables 
between the two groups (Aveyard, 2007). RCTs were therefore the main focus for critical 
appraisal whilst the inclusion of pilot, cohort and case study designs were also considered 
in order to provide a more comprehensive review.  
 
The information contained within the studies and relevant to this review was extracted and 
is included in two tables. Table 1 (below) includes relevant information from the studies 
that aim at increasing positive behaviours; Table 2 (below) includes relevant information 
from the studies that aim at decreasing negative behaviour.  
 
The next section reports the outcomes from a number of studies that have incorporated 
motivational interviewing into their intervention with the aim of increasing positive 
behaviours. Positive behaviours include increasing adherence to medication and increasing 
treatment retention. Both of these behaviours are evaluated separately. Subsequently, this 
review evaluated the outcomes from a number of studies that have incorporated 
motivational interviewing into their intervention with the aim of reducing negative 
behaviours. Negative behaviours include decreasing use of more than once substance and 
decreasing use of a single substance. Both of these behaviours are evaluated separately. 
Finally the review considers the evidence overall and the degree to which motivational 
based approaches are effective in increasing positive behaviours and decreasing negative 
behaviours amongst individuals with severe mental health problems, suggesting areas for 
future research.   
 
   
 
 
 
 
 
 Motivational based approaches aimed at increasing ‘healthy’ behaviours amongst 
individuals with severe mental health problems 
 
Thirteen studies were identified that utilised motivational based approaches to increase 
healthy behaviours amongst individuals with severe mental health (SMH) problems. These 
can be categorised into two types, namely: (i) increasing adherence to antipsychotic 
medication (Table 1, below) and (ii) increasing treatment retention (Table 2, below). The 
next section of this review evaluates the efficacy of these motivational based approaches in 
increasing behavioural change amongst individuals with SMH problems. 
 
Section 1.0 Increasing adherence to medication amongst individuals with severe 
mental health problems 
 
This section reports on the outcomes from motivational based interventions that aimed to 
increase adherence to medication, first by offering a brief overview of the interventions 
and outcomes implemented in these studies and then discussing their findings. From Table 
1 (below) it can be seen that eight studies aimed to increase medication adherence. Five of 
the eight studies used an intervention called Compliance Therapy (CT). Developed by 
Kemp, Hayward, Applewhaite, Everitt & David (1996), CT is an amalgamation of 
Cognitive Behavioural Therapy and Motivational Interviewing. CT is designed to be a 
more directive motivational based intervention adapted towards the cognitive difficulties 
faced by individuals with SMH problems. CT is delivered in a manualised form, over a 
period of approximately six sessions. Of the three remaining studies that did not use CT, 
one used a precursor to CT called ‘medication self management therapy’ (Hayward, Chan, 
Kemp, Youle & David, 1995), and two studies used a derivative of CT called Adherence 
Therapy (AT) (Gray, Leese, Bindman, Becker, Burti, David, Gournay, Kikkert, Koeter, 
Puschner, Schene, Thornicroft & Tansella, 2006). The eight interventions being reviewed 
varied in duration from four sessions to eight sessions. 
 
Outcome from the CT interventions were measured via three methods. First, behavioural 
change or compliance to medication was measured using ratings based upon clinician 
observation. Second, cognitive changes towards compliance to medication were measured 
using a self report attitude to medication measures. Third, changes in SMH 
 
symptomatology were measured by observer ratings of psychotic symptoms. Not all 
studies measured these three areas of change, and this review was primarily concerned 
with behavioural change, although other available outcomes were reported.  
 
The findings of the motivational based approaches that aimed to increase adherence to 
medication are discussed below. Of the eight studies that used CT based approaches to 
increase medication adherence, four studies reported either a significant behavioural, 
symptomatic or an attitudinal change following the use of CT. A randomised controlled 
trial (RCT) by Kemp et al., (1996), a follow up at 18 months (Kemp, Kirov, Everitt, 
Hayward & David, 1998) and a cluster controlled RCT by Gray, Wykes, Edmonds, Leese 
and Gournay (2004) reported changes at a behavioural level (i.e. increased medication 
adherence) compared to control groups. In addition to this behavioural change, Kemp et 
al., (1998) reported that the group receiving CT improved significantly on measures of: 
insight, drug attitudes and global functioning at three months. With the contribution of 
booster sessions, these effects were maintained at 6, 12 and 18 months. Despite these 
cognitive and behavioural changes, this did not translate into reduced symptomatology. 
Kemp et al., (1996; 1998) observed that amongst their mixed sample, participants with a 
diagnosis of schizophrenia had a less favourable outcome compared to participants with a 
diagnosis of severe affective disorders. Gray et al., (2004) reported that service users of 52 
Community Mental Health Nurses (CPNs) trained to deliver CT in a generalised routine 
setting, reported significant behavioural increases in compliance to medication. This 
outcome did translate to reduced symptomatology compared to the treatment as usual 
group at six months. The study by Gray et al., (2004) reported that it demonstrated strong 
generalisability to other clinical settings. However, I would question these claims of strong 
generalisability made by the author on the basis that the study excluded substance using 
participants. High rates of substance use are reported amongst individuals with SMH 
problems. Approximately 50 percent of individuals will develop a substance use disorder 
at some point during their lives and approximately 25 percent will display current 
substance dependence or abuse (Rachbiesel et al., 1999). Therefore excluding substance 
using participants may represent a selection bias. A lack of assessment of fidelity to 
treatment reduces the confidence that the treatment was delivered as intended, thereby 
reducing confidence in the finding. There is no additional cluster RCTs to corroborate 
these outcomes. Variations in pre-existing therapeutic relationship prior to the intervention 
may reduce confidence that the efficacy of the outcome is due to the CT component alone. 
 
In the study by Gray et al. (2004) the CPNs trained to deliver the CT treatment were not 
blind when selecting service users and may have selected participants based upon positive 
pre-existing relationships. Similarly, the study by Kemp et al. (1998) was carried out in an 
inpatient setting which may have also offered the opportunity for informal contact with the 
therapist. 
 
Evidence supporting changes at a symptomatic and/or cognitive level comes from two 
studies both using a CT intervention. A RCT by Maneesakorn et al. (2007) and an 
uncontrolled case study by Tay (2007) both reported clinically significant improvements in 
attitude towards medication. Change at a cognitive level did not translate into a 
behavioural change in the study by Tay (2007). Maneesakorn et al. (2007) did not measure 
behavioural change but did report significant improvements in symptomatology and 
satisfaction with medication changes compared to the control group at a two month follow 
up.  Significant improvements were not reported for general functioning or side effects. A 
lack of a control group and lack of blinding limits the ability to draw firm conclusions from 
the study by Tay (2007) as other factors not controlled for (for example, the impact of the 
more structured inpatient environment or the impact of treatment as usual)  may have been 
operating to serve change.  
 
As can be seen from Table 1 (below), four of the eight studies did not report advantages 
over ‘non-specific’ therapy on measures of change which included: medication 
compliance, attitudes to treatment, insight, symptomatology, global functioning or quality 
of life. Four studies therefore did not demonstrate evidence of change either at a cognitive, 
behavioural or symptomatic level following the use of either CT or AT. From Table 1 
(below) it can be seen that with the exception of one study (Gray et al., 2006), these studies 
recruited relatively small sample sizes which ranged from 10 participants (Hayward et al., 
1995) in the study group to 30 participants (Byerly, Fisher, Carmody & Rush, 2005). 
Limited statistical power to detect subtle changes in outcome measures means that the 
possibility the intervention had a desired effect cannot totally be excluded.  
 
A number of other methodological differences exist between studies which may, in part, 
contribute to explaining why outcomes between studies varied. From Table 1 (below) it 
can be seen that a number of studies that did not report a significant behavioural, cognitive 
change towards medication adherence or change in psychotic symptoms, particularly the 
 
RCTs, used follow up periods that were much longer in duration at 12 months (e.g. 
O’Donnell, Donohoe, Sharkey, Owens, Migone, Harries, Kinsella, Larkin & O’Callaghan, 
2003; Gray et al., 2006) compared to studies that reported a significant behavioural 
increase in adherence to medication (for example, Kemp et al., 1996). Whilst, Kemp et al. 
(1998) later demonstrated efficacy over a lengthy period of 18 months, this was the only 
study to use booster sessions. One hypothesis may be that the effect from CT is relatively 
short lasting and therefore amongst those studies that did not report a significant 
behavioural increase in medication adherence outcome, an effect may have been initially 
present, but then later subsided but the follow up period was merely too long to capture 
this. However, the lack any significant behavioural, cognitive change towards medication 
adherence or change in psychotic symptoms change reported either immediately after 
intervention (Hayward et al., 1995) or at 1 month (Byerly et al., 2005) do not support this 
hypothesis.  
 
Kemp et al. (1998) reported that participants diagnosed with schizophrenia demonstrated a 
reduced positive behavioural change compared to the participants diagnosed with severe 
affective disorders. There was a pattern where studies that did not report an increase in 
adherence to medication (O’Donnell et al., 2003; Gray et al., 2006), recruited 
schizophrenia only samples which contrasted to studies that did report an increase in 
adherence to medication (Kemp et al., 1998) where fewer participants (66%) were 
diagnosed with schizophrenia. It is suggested by Kemp et al. (1998) that participants with 
schizophrenia may be less amenable to change compared to participants with other SMH 
diagnoses. Conclusions are limited by the issue that sub-analyses by diagnosis were not 
reported for the remaining studies where samples of mixed SMH diagnoses were used.  
 
Two studies that did not report any significant cognitive, behavioural or symptomatic  
change from the motivational based intervention (Gray et al., 2006; Byerly et al., 2005) 
both report that their samples were already relatively treatment adherent at baseline, thus a 
treatment ‘ceiling effect’ may have been operating which acted to limit any achievable 
outcome. It is possible that studies where baseline motivation is low, then interventions 
that aim to increase this motivation, may have a greater room for effect, compared to those 
studies where motivation is already high at baseline and may contribute to some of the 
variation in outcome between studies. However, baseline motivation is not consistently 
stated in the studies and therefore comparisons cannot be drawn.  
 
 The location of the trial can influence how much additional non-formal contact time 
participants have with therapists or other staff. In-patient settings offer greater opportunity 
for informal contact should the therapist be a current member of staff. Two RCTs; that 
reported either significant behavioural and cognitive improvement (Kemp et al., 1998) or a 
significant cognitive and symptomatic improvement (Maneesakorn et al., 2007) as well as 
an uncontrolled case study by Tay (2007) which reported a significant positive cognitive 
improvement were all carried out in inpatient settings. In contrast the RCTs that did not 
report any significant positive behavioural, cognitive or symptomatic change in adherence 
to medication (O’Donnell et al., 2003 and Gray et al., 2006) were carried out in outpatient 
services. This offers a competing explanation for the variation in outcome reported in these 
studies.  
  
The degree to which studies measured fidelity to the treatment condition varied. For 
example, Tay (2007) was not clear in describing the intervention, the procedure of 
administration or duration. Due to the large number of therapists employed in the study by 
Gray et al. (2006) fidelity to treatment was not assessed. In Gray et al. (2004) the duration 
and intensity of the CT intervention delivered by the CPNs was not assessed and is 
therefore unknown. In the study by Byerly et al. (2005) fidelity was assessed via verbal 
feedback to the principal investigator who was not experienced in CT. Variation in fidelity 
to treatment between studies may therefore offer a competing explanation for variance in 
outcomes. 
 
All studies used outcome measures with reported validity and reliability, with the 
exception of measures of behavioural compliance to medication, which increases 
confidence in their findings. Behavioural adherence to medication was most frequently 
measured using seven point observer ratings scale (CRCS) developed by Kemp et al. 
(1996). In contrast, O’Donnell et al. (2003) used a four point scale which may be less 
sensitive in detecting small but significant changes. This may have contributed to the non-
significant behavioural change reported. Only one study (Byerly et al, 2005) used an 
electronic measure of medication usage ‘pill counting’ which is arguably a more accurate 
measure of compliance. A lack of direct compliance measure is a limitation for all studies 
with the exception of Byerly et al. (2005).  Natural variations in observations of 
behavioural adherence to medication may also account for variations in outcome between 
 
 studies, although the studies stated that observations were corroborated by additional 
external sources.  
  
Summary 
Other than the study by Kemp et al. (1998) there is no other randomised controlled trial 
which demonstrated that the effect of Compliance Therapy upon behavioural change will 
endure past three months, without the availability of booster sessions. In the absence of 
behavioural change, studies have reported change at a cognitive level (Tay 2007; 
Maneesakorn et al., 2007) and at a symptomatic level (Maneesakorn et al., 2007). Both 
these studies reported methodological limitations which reduces confidence in these 
findings. Four studies (O’Donnell et al., 2003; Gray et al., 2006; Byerly et al., 2005; 
Hayward et al., 1995) did not demonstrate a change either at a behavioural, cognitive or 
symptomatic level following a motivational based intervention. Of these four studies, two 
were considered to be the most methodologically rigorous (O’Donnell et al., 2003; Gray et 
al., 2006), which reduces confidence in the efficacy of motivational based approaches. 
However, these two studies also employed the longest follow up periods (12 months). 
Consequently there is no way to confirm whether these studies were effective in the short 
term or not. There is the suggestion by the authors of a ceiling effect in operation amongst 
studies not reporting a significant behavioural change (Gray et al., 2006; Byerly et al., 
2005). Unfortunately none of the studies carried out sub analyses by levels of motivation 
and few reported baseline levels of motivation; therefore this cannot be explored further. In 
summary, the evidence supporting the efficacy of motivational based approaches in 
increasing compliance to medication suggests that it is time limited and that it may only be 
effective amongst participants with lower baseline levels of motivation.  
 
The next section evaluates the outcome from studies that have aimed to increase retention 
to treatment. This is the only other area where motivational based approaches have been 
utilised to increase positive behaviours.  
 
 
  
 
 
 
Table 1. Medication adherence 
 
Study Intervention    
Duration  
 
Control Sample 
Diagnosis 
 
 
Attrition 
Single blinding 
Primary Measures 
Follow up period(s) 
 
Outcome 
Effect  significance at p< 
0.05 
Kemp et al (1996) / 
(1998) 
 
Compliance 
therapy in 
psychotic patients: 
An RCT 
 
RCT 
 
Compliance 
Therapy 
 
4-6 x 10-60mins 
 
 
Booster session at  
3,6,12 months 
 
Supportive 
counselling 
 
5 x 20-60mins 
 
 
 
 
Inpatient 
 
Schizophrenia 
66% 
Severe affective 
disorders  
34% 
 
Study n=22 
Control n=25 
 
31%  
 
No significant  
differences between 
groups at baseline 
 
 
Blind at 6, 12, 18 month 
follow up only 
Observer rated compliance 
(CRCS) 
 
BPRS- symptoms 
GAF- Functioning 
DAI – Drug attitudes 
SAI -Insight 
AMQ- Attitude 
 
0, 3,6,12,18 months 
 
Significant at 0, 3, 6, 12, 
18 months  
 
Non sig 
Sig 
Sig 
Sig 
Sig 
 
 
O’Donnell et al 
(2003) 
 
Compliance 
therapy: A RCT in 
 schizophrenia 
 
RCT 
Compliance 
Therapy 
 
5x30-60mins  
 
 
Non specific 
counselling  
 
5x30-60mins  
 
Inpatient  
 
Schizophrenia  
100% 
 
Study n=27 
Control n=26 
36 % 
 
No significant  
differences between 
groups at baseline 
 
 
 
Yes 
Observer rated compliance 
(4 item scale) 
 
PANSS –symptoms 
DAI –Drug attitudes 
GAF- Functioning 
QLS –quality of life 
SAI -Insight 
12 months 
Non-significant on all 
measures 
 
 
 
 
 
 
 
Gray et al (2006) 
 
Adherence therapy 
for people with 
schizophrenia: 
European 
multicentre 
randomised 
controlled trial. 
Adherence 
Therapy  
 
8 x30-50mins  
 
 
 
 
Didactic Health 
Information 
 
7 x30-50mins  
 
 
Outpatient 
 
Schizophrenia 
100% 
 
 
Study n= 165 
Control=184 
20%  
 
No significant  
differences between 
groups at baseline 
 
Blind 
 
Observer rated compliance  
 
BPRS- symptoms 
MAQ- med adherence  
SAI -Insight 
MCS – quality of life 
 
 
6 months 
Non-significant on all 
measures 
 
 
Study Intervention    
Duration  
 
Control Sample 
Diagnosis 
 
 
Attrition 
Single blinding 
Primary Measures 
Follow up period(s) 
 
Outcome 
Effect  significance at p< 
0.05 
 
RCT 
Byerly et al (2005) 
 
A Trial of 
Compliance is 
Therapy in 
Outpatients With 
Schizophrenia or 
Schizoaffective 
Disorder 
 
Uncontrolled  
Case study 
Compliance 
Therapy 
 
4-6 sessions x 30-
60mins.  
 
 
No control Study = 30 
 
Schizophrenia 
70% 
Schizoaffective 
30% 
 
 
30% 
 
Yes 
Compliance  
MEMS;CRCS;MARS 
 
PANSS –symptoms 
DAI –Drug attitudes 
SAI -Insight 
 
 
 
1 & 5 months 
Non-significant on  
all measures 
 
Gray et al (2004) 
 
Effect of a 
medication 
management 
training for nurses 
on  outcomes for 
patients with 
schizophrenia 
 
Pragmatic RCT 
Compliance 
Therapy training 
amongst  CMHN 
80hr teaching 
 
Unspecified 
duration of 
interventions 
 
 
  26% 
 
 
No 
 
PANSS –symptoms 
 
Observer rated compliance  
DAI – drug attitude 
 
 
 
 
 
6 months 
Significant reduction in 
compliance and symptoms 
(PANSS) 
 
 
 
 
 
 
 
 
Maneesakorn et al 
(2007) 
 
An RCT of 
adherence therapy 
for people with 
Adherence therapy Standard Care  
 
(Therapist time not 
controlled for) 
 
Inpatient 
 
Schizophrenia 
100% 
 
Study n= 16 
12.5% 
 
Yes 
 
No significant  
differences between 
PANSS Symptoms  
 
GAF – Functioning 
DAI- Drug attitudes 
SWAM – satisfaction with 
medication 
Significant 
 
Non-significant  
Significant  
Significant  
 
 
  
Study Intervention    
Duration  
 
Control Sample 
Diagnosis 
 
 
Attrition 
Single blinding 
Primary Measures 
Follow up period(s) 
 
Outcome 
Effect  significance at p<
0.05 
 
schizophrenia in 
Chiang Mai, 
Thailand 
RCT 
Control= 16 groups at baseline 
 
LUNSERS – side effects 
 
2 months 
Non-significant  
 
Hayward (1995) 
 
Medication self 
management: A 
preliminary report 
on an intervention 
to improve 
medication 
compliance 
Medication self 
management 
therapy 2-3 x 
30mins 
Non directive 
discussion  
(Therapist time 
controlled for) 
Schizophrenia 
70% 
 
Affective 
disorder (30%) 
 
Study = 10 
Control=11 
25% 
 
Yes 
 
No significant  
differences between 
groups at baseline 
 
AMQ – Medication 
attitudes 
InQ – Insight  
BPRS - symptoms 
Observer rated compliance  
 
Immediately after 
intervention 
Non-significant on all 
measures 
Tay, Sim-Eng 
Clara et al (2007) 
 
Compliance 
therapy: An 
intervention to 
improve inpatients' 
attitudes toward 
treatment. 
 
Case study 
Compliance 
therapy 
 
Group session 
(unspecified 
length) 
 
N/A Study= 69 
 
Not specified 
15% 
 
Not blind 
DAI – drug attitude 
CRCS – compliance  
 
9 months 
 
Significant increase in 
attitudes towards treatment 
  
Section 1:1 Increasing treatment retention amongst individuals with severe mental 
health problems. 
 
This section evaluates four studies that have been published which aim to increase 
retention to treatment amongst samples with severe mental health (SMH) problems see 
Table 2 (below). The four studies are considered broadly comparable in their use of a brief 
intervention consisting of a single motivational based interview and also their use of an 
appropriate control group. Of these four studies, three studies reported a significant 
increase in treatment retention, however only one reported an increase in retention beyond 
one month.  
 
The study with the longest duration of outcome was a pilot by Martino, Carroll, O’Malley 
and Rounsaville, (2000) which reported a significant increase in attendance over three 
months. The outcomes from the remaining two studies that reported a significant increase 
in attendance were much more brief and required the participant to contact the treatment 
provider (Swanson, Pantalon & Cohen, 1999) or required the participant to attend their 
first appointment with the treatment provider (Steinberg, Ziedonis, Krejci & Brandon, 
2004). However, a number of methodological issues concern the studies by Martino et al. 
(2000) and Swanson et al. (1999). Neither study reported that they had implemented 
trained mental health professionals to administer the intervention, neither did they report 
having used a manualised approach that was assessed for fidelity to treatment. Therefore it 
is uncertain that the intervention was delivered as intended, and replication to general 
service settings is impeded. Neither study controlled for therapists’ time in the control 
group. Consequently the outcome may have resulted from therapist attention rather than 
the intervention per se. Less than half the participants reported SMH problems and the 
sample size in the Martino et al. (2000) study consisted of just 13 participants. In addition, 
Martino et al. (2000) and Steinberg et al. (2004) did not report blinding which offers a 
competing explanation for their outcomes. Consequently these limitations require these 
results to be treated with caution.  
 
Only one study did not report significantly increased attendance (Baker, Lewin, Reichler, 
Clancy, Carr, Garrett, Sly, Devir & Terry, 2002). Unlike those studies that did report 
  
efficacy (Martino et al., 2000; Swanson et al., 1999; Steinberg et al., 1999), outcomes were 
measured over a lengthier three month period. The study reported that high levels of 
substance dependence amongst the participants at the start of the intervention may have 
contributed to their non-significant increase in attendance and that a single hour of 
intervention was insufficient to contribute to any positive change. The number of 
participants with SMH problems was relatively small (37%), therefore the contribution of 
these outcomes to the debate is somewhat limited. In addition, a number of methodological 
limitations reduce confidence further, notably a lack of: blinding, independent assessment 
of treatment fidelity and control for therapists’ attention.  
 
Summary  
Three of four studies (Martino et al., 2000; Swanson et al., 1999; Steinberg et al., 1999), 
reported a significant increase in treatment attendance from a motivational based approach 
in increasing treatment attendance, but these outcomes were limited in duration, 
concerning either initial contact with services or attendance at the initial appointment. It 
should be noted that longer duration measures were not taken and therefore longer 
durations of effect may have been present but could not be measured. Although, where 
longer duration outcomes were measured, efficacy was not reported (Baker et al., 2002). 
Out of the four studies, the study by Steinberg et al. (2004) appears to be the most 
methodologically rigorous and suggest motivational based approaches are effective in 
increasing treatment retention amongst individuals with diagnoses on the SMH spectrum. 
The remaining three studies all have a number of methodological limitations which reduces 
confidence in their findings. Where motivational based approaches have demonstrated 
efficacy, it stems from minimal intervention (that is, a single motivational interview, which 
indicates an efficient use of resources). However, follow up periods are very brief, often 
consisting of attendance to one appointment only and there is a paucity of studies 
measuring longer term outcomes. Despite this, the outcomes reported were considered 
valuable because unless a service user accesses services, then regardless how effective the 
service is, the individual cannot be supported.  
 
The next section evaluates interventions that have incorporated motivational interviewing 
in aiming to decrease negative or unhelpful behaviours amongst individuals with severe 
  
mental health problems, before finally a conclusion is drawn on the overall efficacy of 
motivational approaches amongst this population. 
 
 
 
Table 2: Studies aimed at increasing treatment retention  
 
 
Author / Title Intervention   
 
Duration  
 
Sample 
 
Diagnosis 
 
Context  
 
Control 
 
Control for therapist 
time 
Attrition 
 
Single blinding 
Primary Measures 
 
Follow up period(s) 
 
Outcome 
 
Effect  significance 
at p< 0.05 
Swanson et al 1999 
 
MI and treatment 
adherence among 
psychiatric and dually 
diagnosed patients 
MI 
 
1x 60min + 1x15 min 
feedback 
Psychosis 45% 
Affective 40% 
Other 15% 
 
Study =57 
Control = 64 
 
Outpatient 
Treatment as usual  
 
Therapist time not 
controlled for 
Not stated 
 
Single blind 
Attendance data 
For 1st appointment 
Significant 
 
Baker et al (2002)  
 
MI among psychiatric 
inpatients with 
substance use 
disorders 
 
RCT 
MI + CBT interview  
 
1 x1hr 
 
Affective 53% 
Schizophrenia 37% 
 
 
Study n= 79 
Control n= 81 
 
Inpatient 
Advice  
 
1 x1hr 
 
 
Therapist time not 
controlled for 
Not stated  
 
 
Not stated 
Attendance over 3 
months to programme 
Non significant 
Steinberg et al (2004) 
 
MI with personalised 
feedback: A brief 
intervention for 
motivating smokers 
with schizophrenia to 
seek treatment for 
tobacco dependence 
MI interview  
 
1 x 40 min 
 
Schizophrenia /  
schizoaffective 
disorder 100% 
 
Study n = 32 
 
Control  
Psycho-education n= 
34  
Psycho 
Education/Advice 
1 x 40 min  
 
Therapist time 
controlled for 
 
Not stated 
 
Not stated 
Contact treatment 
provider. 
Significant treatment 
contact within 1 
month for study group 
 
 
  
 
RCT 
 
Advice n=12 
 
Outpatient  
Author / Title Intervention   
 
Duration  
 
Sample 
 
Diagnosis 
 
Context  
 
Control 
 
Control for therapist 
time 
Attrition 
 
Single blinding 
Primary Measures 
 
Follow up period(s) 
 
Outcome 
 
Effect  significance 
at p< 0.05 
Martino et al (2000) 
 
Motivational 
Interviewing with 
Psychiatrically Ill 
Substance Abusing 
Patients 
 
Pilot 
MI 
 
1 x 1hr 
 
Psychosis 52% 
Affective 48%  
 
Study n= 13 
Control n= 10 
 
Outpatient  
 
Standard 
preadmission 
interview 
 
Therapist time not 
controlled for 
Not stated  
 
Unclear blinding 
Attendance data 
Over 3 months 
Significant increase in 
days of attendance for 
study group. 
 
 
 
 
  
Part 2: Decreasing negative behaviours amongst individuals with severe mental 
health problems 
 
This section evaluates the studies that have implemented motivational based approaches 
amongst individuals with severe mental health (SMH) problems with the aim of decreasing 
problematic behaviours. Table 3 (below) reports information from 18 studies that have 
used motivational based approaches including: type and length of intervention, sample 
sizes, controls used, participant diagnoses and finally outcome data. The 18 different 
studies can be divided into those studies (n=9) that did not report substance specific 
outcomes, rather they grouped and reported the outcomes from different substances 
together (poly-drug reduction) and studies (n=9) that did report substance specific 
outcomes (substance specific reduction). The outcomes from nine studies that aimed to 
reduce poly-drug use are discussed first, followed by the outcomes from the nine studies 
that measured substance specific change.  
 
 
Section 2:0 Decreasing poly-drug use amongst individuals with severe mental health 
problems. 
 
Nine studies intervened using motivational based approaches with the aim of reducing 
usage of a variety of different substances and when they reported the outcomes the results 
from changes in use from various different substances were reported together. From Table 
3 (below) it can be seen that the most common substances reported as being used by 
participants were alcohol and cannabis. A number of studies also reported cocaine and 
amphetamine use, and a minority of studies reported the use of heroin. The nine studies 
were relatively consistent on the severe mental health diagnoses amongst the samples used. 
The majority of participants used within each study were diagnosed with schizophrenia, 
with rates ranging from 62.5% to 100%. Only one study (Bellack, Bennett, Gearon, Brown 
& Yang, 2006) reported that schizophrenia was a minority diagnosis amongst participants 
(40%), whereas two studies (Kemp, Harris, Vurel & Sitharthan, 2007; Johnson, 
Thornicroft, Afuwape, Leese, White, Hughes, Wanigaratne, Miles, & Craig, 2007) did not 
report this information. All nine studies measured substance use as their primary outcome. 
  
There was variation in whether change in substance use was measured by participant self-
report, clinician ratings or analysis of urine. A number of secondary outcomes measured 
varying combinations of: symptomatology, substance dependence and general functioning. 
Two studies (McCoy, Devitt, Clay, Davis, Dincin, Pavick, & O’Neill, 2003; Carey, Carey, 
Maisto & Purnine, 2002) also measured participants’ stage of change using the ‘Substance 
Abuse Treatment Scale’ (McHugo, Drake, Burton, & Ackerson, 1995) and the ‘Stages of 
Change Readiness and Treatment Eagerness Scale’ (Miller & Tonigan, 1996) respectively. 
(Stage of change refers to the stage in the motivational cycle that an individual is at, for 
example, pre-contemplation, contemplation or action stage etc (Prochaska & Norcross, 
2001). 
 
From Table 3 (below) it can be seen that four of the nine studies adopted a one to one 
intervention approach, four studies adopted a group intervention approach and one study 
trained clinicians to deliver a motivational based approach in a routine clinical setting. In 
contrast to the studies which used a very similar manualised intervention (Compliance 
Therapy), to increase adherence to medication (Section 1.0), there was much greater 
variation in the interventions adopted by the studies that aimed to decrease poly-substance 
use. The studies that intervened on a one to one basis combined motivational interviewing 
with a variety of cognitive behavioural, harm reduction and psycho-educational approaches 
of varying proportions, but were generally brief in their duration, consisting of three to six 
hours. The exception was Barrowclough, Haddock, Tarrier, Lewis, Moring, O’Brien, 
Schofield, and McGovern, (2001) who included a 16 hour family intervention in addition 
to the 29 hour individual intervention. The group based interventions were more varied 
both in type and duration. Bellack et al. (2006) integrated six different interventions into a 
comprehensive package; McCoy et al. (2003) involved multifaceted residential treatments 
programme and duration of intervention was generally longer, ranging from nine hours to 
eighteen months.  
 
The outcomes from the nine studies that used a motivational based intervention indicated 
that a majority of studies (eight out of nine) reported a significant reduction in poly-drug 
use at the end of treatment. Kavanagh, Young, White, Saunders, Wallis, Shockley, Jenner 
and Clair (2004) reported the longest duration of effect: poly-drug use reduction was 
  
maintained at 12 months post treatment. However, the study reported a significant 
confounder: living with a carer or partner predicted positive outcome and more participants 
in the intervention group lived with a carer or partner. Barrowclough et al. (2001) reported 
that abstinence was maintained at three months, but subsequently diminished at nine month 
follow up. Carey et al. (2002) also reported a diminishing effect at a three month follow 
up, suggesting the effect for the motivational based approach is time limited. Kemp, 
Harris, Vurel and Sitharthan (2007) was the only study to carry out an individual 
intervention and to not report a reduction in quantity of poly-drug use; however the study 
did report a reduction in frequency of poly-drug use. This outcome may be considered 
clinically significant on the basis that changes in frequency of drug use have been shown to 
be a more reliable predictor of outcome compared to changes in quantities of drug use 
(Project MATCH Research Group, 1997).  
 
Amongst the group interventions, all four studies reported a significant reduction in poly-
drug use at the end of treatment with the longest duration of effect reported by James, 
Preston, Koh, Spencer, Kisley and Castle (2004) at three months post treatment. The 
remaining three studies did not measure change beyond end of treatment so duration of 
effect remained unknown. Only one study (Johnson et al., 2007) did not report any change 
in poly-drug use at end of 18 months treatment. However, with no assessment of fidelity to 
treatment and little information provided on variability of clinician experience, it is 
conceivable the outcome may have resulted from a sub-optimal intervention. A number of 
other methodological limitations may have contributed to variation in findings. Measures 
of substance use varied between studies, with the majority relying on self report measures 
(timeline follow back and the opiate treatment index) or ratings by assessors (case manager 
rating scale). These measures report good psychometric properties and yield reliable 
retrospective data on addictive behaviours (Sobell & Sobell, 1992). However, self report 
measures are still susceptible to recall difficulties and response bias (Miller, 1987). With 
the exception of two studies (Bellack et al., 2006; Johnson et al., 2007), the size of the 
samples (which ranged from 6 to 39) were relatively small / modest. Small sample sizes 
may have yielded results that were down to chance, which requires these results to be 
treated with caution (Burns & Grove, 2005).    
 
  
A number of other significant outcomes were reported following the motivational based 
approaches, these included improvements on measures of motivation, symptomatology, 
substance dependence and general functioning. From Table 3 (below), it can be seen that 
two studies (McCoy et al., 2003; Carey et al., 2002) measured the impact upon motivation 
and both reported significant increase in motivation at end of treatment. Carey et al. (2002) 
was the only study to measure effect beyond end of treatment and reported that motivation 
declined to non-significant levels at three months, indicating the effect of the motivational 
based intervention is time limited. Neither of these studies used a control group to control 
for the effect of the intervention, therefore other factors (for example, ‘treatment as usual’ 
may have contributed to the change). This issue reduces confidence that the reported 
increase in motivation was due to the intervention alone. Of four studies that measured 
changes in symptomatology, three studies reported a significant reduction on outcome. The 
longest duration of effect was a reduction in negative symptoms at nine months 
(Barrowclough et al., 2001). Both James et al. (2004) and Bradley, Baker & Lewin, (2007) 
reported a significant reduction in positive and negative symptoms at three months and at 
end of treatment respectively. One study (Kemp et al., 2007) did not report a significant 
change in symptomatology. Of the three studies that measured the impact of the 
motivational based approach on substance dependence, two reported a significant 
reduction, James et al. (2004) at three months and Bellack et al. (2006) at end of treatment. 
Kemp et al., (2007) did not report any significant reduction in dependence at six months. 
Of the three studies that measured the impact upon general functioning, two studies 
(Barrowclough et al., 2001; Bellack et al., 2006) reported a significant increase in general 
functioning at nine months and end of treatment respectively, whereas Kemp et al. (2007) 
did not report a significant increase in general functioning at six months.  
 
Despite the positive changes reported for symptomatology, substance dependence general 
functioning and motivation, a number of methodological limitations reduce confidence in 
these findings. It can be seen from Table 3 (below) that of the studies that used a control 
group, only one study (Bellack et al., 2006) controlled for the effect of the additional 
therapist attention resulting from the motivational based approach (reporting a significant 
reduction in substance use and increase in general functioning at end of treatment). 
Consequently, the reduction in substance use reported by the remaining five studies that 
  
did not control for additional therapist attention may have been due to the additional 
therapist attention and not just the manualised treatment.  The majority of studies reported 
that whilst raters were blind to the treatment condition, it was not possible for the 
facilitators to be. Lack of facilitator blinding may be a problem when researchers are the 
originators of the package and may offer a competing explanation for the effects reported. 
Lastly, studies did not consistently report levels of baseline motivation and substance 
dependence, and given that brief interventions are effective among people with lower 
levels of dependence (Mattick and Jarvis, 1993), it is uncertain how effective these 
interventions are likely to be for the varying levels of dependency and motivation that 
might be experienced in routine clinical settings. Despite these methodological limitations, 
the studies that were the more methodologically rigorous (Barrowclough et al., 2001; 
James et al., 2004; Bellack et al., 2006) tended to be those that reported the more enduring 
change and therefore I would argue that the motivational approach does demonstrate 
effective change in poly-drug use, symptomatology, motivation, substance dependence and 
general functioning. However these interventions also tended to be the studies that used 
more comprehensive approaches. It does not seem unlikely that interventions that involve a 
greater rather than a fewer number of interventions should demonstrate efficacy, and of 
course we are unable to ascertain the relative contribution of the motivational interview to 
the outcome as a whole.  
 
 
Summary 
The vast majority of studies (Barrowclough et al., 2001; Kavanagh et al., 2004; Carey et 
al., 2002; Kemp, et al., 2007; James et al., 2007; Bellack et al., 2006; McCoy et al., 2003; 
Bradley et al., 2007) reported a positive change in poly-drug use at the end of treatment. 
Additionally, change in either: symptomatology, motivation, substance dependence or 
general functioning was reported by these studies. A number of methodological issues 
reduce confidence in these findings, notably: small sample sizes, inconsistency in 
controlling for the additional therapists’ time, and inconsistent measures of substance 
dependence at baseline. It is not possible to know the direct implications of these 
methodological issues upon individual outcomes; however the studies that were the more 
methodologically rigorous (Barrowclough et al., 2001; James et al., 2004; Bellack et al., 
  
2006) tended to be amongst those that reported the more enduring change. I would 
therefore argue that motivational approaches do demonstrate reductions in substances 
when the changes are reported together.   
 
The general brevity of the follow up periods used does not allow for an assessment of 
duration of effect. The outcomes from the minority of studies that measured duration of 
effect over time (Carey et al., 2002; Barrowclough et al., 2001), indicated a decline 
suggesting that the effect of motivational based approaches is time limited. This is a 
pattern also reported amongst the general substance using population (Hettema, Steele & 
Miller, 2005). An additional finding was that group interventions appeared to be effective. 
Group interventions may also have two possible benefits over individual therapy. First, 
group interventions may establish social support away from substance using peers (Carey 
& Carey, 1995). Second, group interventions may be a more efficient use of resources 
compared to individual therapies.  
 
It is not known which substance motivational based approaches are effective for because 
outcomes for all substances are grouped and reported together. The next section evaluates a 
number of studies that have measured the change in use upon specific substances following 
a motivational based approach. 
 
Table 3. Decreasing behaviours (Poly-substance use) 
 
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
Manualised? 
 
Treatment 
fidelity? 
 
Experienced 
professionals
? 
Diagnosis 
 
 
Sample 
 
 
Context  
 
Control used 
 
 
Controlled for 
therapist time  
Attrition 
 
 
Single 
blinding 
Measures 
 
 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 
0.05 
Barrowclough  et al  
2001/ Haddock et al 
2003 
 
RCT of MI, CBT 
and Family 
Intervention for 
patients with co-
morbid 
schizophrenia and 
substance use 
disorders 
 
RCT – Individual  
MI+CBT+ 
Family intervention +  
 
29 hr individuals 
 
+ 16 hr family 
 
 
Alcohol 
Cannabis 
Cocaine 
Amphetamines 
Heroin 
 
 
Manualised 
 
Yes  
 
 
Yes 
Schizophrenia 
spectrum 100% 
 
 
 
Study n=18 
Control n=18 
 
 
 
 
Outpatient  
Routine Care 
 
No control for 
therapist time 
 
6% 
 
 
Blind 
Functioning: 
GAF-SFS 
 
Symptoms 
PANSS  
 
Substance use: 
TLFB 
 
 
 
 
End of treatment, 
3, 9 months 
Significant improvement in 
functioning (GAF) and 
negative symptoms 
(PANSS) at 9 months. 
 
 
Increase in abstinent days 
from baseline to 3 month 
follow up, not maintained at 
9 months  
 
 
Kavanagh et al 2004 
 
A brief motivational 
intervention for 
substance misuse in 
recent onset 
psychosis. 
 
 
PILOT-Individual 
MI + CBT 
 
3 x 1 hours  
 
Weekly follow up 
telephone calls  
 
Alcohol  
Cannabis  
Amphetamines  
Manualised 
 
 
Yes  
 
Yes  
First episode 
schizophrenia 
100% 
 
 
Study n=13 
Control n=12 
 
Outpatient 
 
Standard care and 
advice.  
 
No control for 
therapist time 
 
25% 
 
 
Blind 
Substance use:  
OTI (drug check) 
 
3,6,12 months 
Significant reduction in 
quantity of poly-drug use 
maintained at 12 months. 
 
 
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
Manualised? 
 
Treatment 
fidelity? 
 
Experienced 
professionals
? 
Diagnosis 
 
 
Sample 
 
 
Context  
 
Control used 
 
 
Controlled for 
therapist time  
Attrition 
 
 
Single 
blinding 
Measures 
 
 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 
0.05 
 Cocaine 
 
Carey et al. 2002 
 
 The feasibility of 
enhancing 
psychiatric 
outpatients 
readiness to change 
their substance use 
 
 
Case study – 
Individual 
MI 
 
4 x  30-60 min  
 
Alcohol   
cocaine   
cannabis  
Manualised  
 
 
Yes 
 
Not stated 
Schizophrenia 
spectrum 73% 
Psychosis not 
specified 20% 
bipolar 7% 
 
Study =22 
 
Outpatient  
No control 20%  
 
 
Blind 
Stages of change- 
SOCRATES  
 
 
 
 
 
Substance use- 
TLFB - (self 
report) 
AUS / OTI 
(clinician rating) 
 
 
 
 3 months 
Significant increase in 
motivation at 0 months, 
dissipated at 3 month follow 
up 
 
 
 
Significant reduction in 
poly-drug use. Dissipated at 
3 month follow up 
 
 
 
Kemp et al 2007 
 
 
Stop using stuff: 
trial of a drug and 
alcohol intervention 
for young people 
with co-morbid 
mental illness and 
MI + CBT  
 
4-6 hours 
 
Alcohol  
Cannabis 
 
 
Manualised 
 
No 
independent 
treatment 
fidelity 
 
Yes  
Schizophrenia 
spectrum  
Psychotic mood 
disorder 
Unspecified % 
 
 
Study n=10 
Control n=6 
Standard care  
 
No control for 
therapist time 
 
N/A 
 
 
Rater not 
blind and 
provided 
treatment  
Symptoms – 
PANSS, DASS  
 
Functioning- 
QoLS 
 
Dependence – 
DAST -10, AUDIT 
 
Non significant reduction 
 
 
 
Non significant reduction 
 
 
Non significant reduction 
 
 
 
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
Manualised? 
 
Treatment 
fidelity? 
 
Experienced 
professionals
? 
Diagnosis 
 
 
Sample 
 
 
Context  
 
Control used 
 
 
Controlled for 
therapist time  
Attrition 
 
 
Single 
blinding 
Measures 
 
 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 
0.05 
drug and alcohol 
problems 
 
PILOT 
 
 
Outpatient 
Substance use- 
TLF 
6 months  
 
Significant  reduction in 
poly-drug frequency only 
James et al (2004) 
 
A group 
intervention which 
assists patients with 
dual diagnosis 
reduce their drug 
use: An RCT 
 
Group RCT 
Group MI + CBT +HR 
6 x 1.5 hrs  
 
Alcohol 
Cannabis 
Cocaine  
 
 
 
Manualised  
 
Yes 
 
Yes 
Schizophrenia 
62.5%  
Other psychoses 
37.5% 
 
 
Study n= 29 
Control n=29 
 
Outpatient  
 
 
1 hr education + 
Standard Care 
 
 
(No control for 
therapist time) 
12% 
 
 
 
Blind 
 
Symptoms- 
BPRS/BSI 
 
Dependence-  
DAST, AUDIT 
 
Substance use – 
OTI 
 
3 month  
Significant  reduction in 
symptoms 
 
Significant reduction in 
dependence. 
 
Significant reduction in 
poly-drug use 
Bellack et al (2006) 
 
An RCT of a new 
behavioural 
treatment for drug 
abuse in people with 
severe and 
persistent mental 
illness 
 
Group RCT 
Group MI/CBT/Social 
skills training/ 
HR/urinalysis 
contingency/relapse 
prevention 
 
6 months 
 
Cocaine  
Heroin 
Cannabis 
Manualised  
 
Yes  
 
Yes 
 
 
 
 
 
Schizophrenia 
40% 
55% Affective 
5% other 
 
 
Study n=61 
Control n =49 
 
Outpatient  
6 month 
manualised control. 
Intervention 
 
(Controlled for 
therapist time) 
27% 
 
 
Blind 
Substance use – 
urinalysis 
 
Dependence –ASI, 
SESS 
 
Quality of life –
BQLS, SFS. 
 
 
End of treatment 
Significant reduction 
  
Non-significant  
 
 
Significant  
 
 
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
Manualised? 
 
Treatment 
fidelity? 
 
Experienced 
professionals
? 
Diagnosis 
 
 
Sample 
 
 
Context  
 
Control used 
 
 
Controlled for 
therapist time  
Attrition 
 
 
Single 
blinding 
Measures 
 
 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 
0.05 
only 
 
 
 
 
 
McCoy et al (2003) 
 
Gaining Insight: 
Who benefits from 
residential 
integrated treatment 
for people with dual 
diagnoses? 
 
Group Case-study 
Group MI + CBT + 
urine testing + 
residential treatment  
18 months 
 
Alcohol  
Cannabis  
Cocaine 
 
 
Not specific 
 
 
 
MH 
professional 
trained  
 
Not stated 
Schizophrenia 
74%  
10% bipolar 
16% affective. 
 
Study n=38 
 
Long term 
residential 
No control 29% 
 
N/A 
Substance use: 
Urinanalysis 
CAUS 
CDUS 
 
Motivation-  
SATS  
 
 
6,12,18 during 
treatment  
Significant  
reductions 
on all measures  
 
 
Significant advance 
 
Bradley et al 2007 
 
Group intervention 
for coexisting 
psychosis and 
substance use 
disorders in rural 
Australia: Outcomes 
over 3 years 
 
Group MI + CBT  
 
60-90 mins x 28 (mean) 
sessions  
 
Alcohol  
cannabis  
     
 
 
Not 
manualised 
 
No 
independent 
treatment 
fidelity 
 
Unknown if 
MH 
Schizophrenia 
79.5%  
schizoaffective 
7.7%  
Bipolar 12.8%  
 
Study n=39 
 
Outpatient  
No control N/A 
 
 
N/A 
 
Symptomatology- 
LSP 
 
 
Substance use- 
CMRS 
 
 
End of treatment 
only  
Significant reduction  
 
 
 
Significant reduction  
 
 
 
  
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
Manualised? 
 
Treatment 
fidelity? 
 
Experienced 
professionals
? 
Diagnosis 
 
 
Sample 
 
 
Context  
 
Control used 
 
 
Controlled for 
therapist time  
Attrition 
 
 
Single 
blinding 
Measures 
 
 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 
0.05 
Group Case study  professional 
 
 
 
 
 
 
 
       
Johnson et al (2007) 
 
Effects of training 
community staff in 
interventions for 
substance misuse in 
dual diagnosis 
patients with 
psychosis 
 
CLUSTER RCT 
 
Training course for case 
managers 
 
5 day training course 
MI+CBT  
 
 
Alcohol   
Unspecified drugs 
Manualised 
 
 
No  
 
 
Yes 
Schizophrenia  
Non affective 
psychosis 
Bipolar 
Unspecified % 
 
 
Study n=127 
Control n=105 
 
Outpatient  
 
CMHT caseload 
 
Not controlled for 
therapists time 
38%  
 
No 
Substance use: 
MAP (self report) 
 
  
 
Relapse rates 
(inpatient bed use) 
 
 
 
18 months 
Non- significant reduction in 
drugs and alcohol 
 
 
 
Non significant bed use 
AUDIT- Alcohol Use Disorders Identification Test; AUS – Alcohol use scale; BQLS-Brief Quality of Life Scale; CAUS – Clinician Alcohol Use Scale;  CDUS- Clinician 
Drug Use Scale CMRS- Case Manager Rating Scale; DASS- DAST-10- Drug Abuse Screening Test; ; GAF- Global Assessment of Functioning; PANSS- Positive and 
Negative symptom scale; LDQ- Leeds Dependency Questionnaire; LSP- Life Skills Profile; MAP- Maudsley Addiction Profile; Opiate Treatment Index- OTI; SATS – 
Substance Abuse Treatment Scale ; SDS SES - SFS- Short form survey; SOCRATES Stages of Change Readiness and Treatment Eagerness Scale; TLFB- Time Line Follow 
Back
  
Section 2:1 Substance specific interventions 
 
Nine studies aimed to reduce substance use using motivational based approaches and 
reported change for individual substances. The studies contained in this section are 
reported by individual substance, this contrasts with the studies contained in section 2:0 
where outcomes from various substances are grouped together. Five of the nine studies 
aimed to reduce usage of a single substance; it can be seen from Table 4 (below) that three 
studies aimed to reduce tobacco use, one study aimed to reduce alcohol use and one study 
aimed to reduce cannabis use. The remaining four studies aimed to reduce a combination 
of different substances including: alcohol, cannabis, amphetamines, cocaine and tobacco. 
The primary outcome for all of the studies was change in substance use. A number of 
secondary outcomes were measured and consisted of varying combinations of: 
symptomatology, motivation, substance dependence and general functioning. From Table 4 
(below) it can be seen that the majority of interventions integrated motivational 
interviewing (MI) with cognitive behavioural therapy (CBT), three studies implemented a 
pharmacological intervention (nicotine replacement therapy), in addition to the MI and 
CBT intervention, and two studies used MI only. Rather than adopting an available 
standardised motivational based approach, the interventions were frequently developed by 
the individual authors. From Table 4 (below) it can be seen that the duration of the 
motivational based approaches were typically brief ranging from a brief single session to 
ten sessions. Participants recruited were mostly diagnosed on the schizophrenia spectrum 
(57% to 100%), the exception being two studies (Baker, Lewin, Reichler, Clancy, Carr, 
Garrett, Sly, Devir & Terry 2002; Kisely & Preston, 2006b) where diagnoses on the 
schizophrenia spectrum were in the minority.  
 
The outcomes indicate that all nine studies reported a significant reduction in either 
alcohol, tobacco or cocaine use by participants who received the motivational based 
approach. However, in only five of these studies were these reductions significantly greater 
than that observed in the control group. A significant reduction in days using alcohol was 
reported in a controlled pilot by Graeber, Moyers, Griffith, Guajardo, and Tonigan (2003). 
A number of methodological issues require this outcome to be treated with caution. There 
was no assessor blinding which offers a competing explanation to the finding. There was 
  
no independent assessment of fidelity to treatment, therefore it is unknown whether the 
intervention was delivered as intended. The three studies that evaluated changes in tobacco 
use all reported a significant reduction in tobacco use. The longest duration of effect was 
reported by Baker, Richmond, Haile, Lewin, Carr, Taylor, Jansons, and Willhelm (2006a) 
where reduction in tobacco use was evident at twelve months after end of treatment. 
However, this reduction was only present in those participants who completed all of the 
treatment sessions. Ziedonis and George (1997) reported that nearly half of the participants 
reduced consumption of tobacco by 50% with 13% of this 50% reporting abstinence after 
six months post treatment.  However, the study was vague in its description of the 
intervention used and did not employ a control group, so it is uncertain if the change was 
due to the intervention alone or whether other confounding variables may have contributed 
to change. Kisely and Preston (2006) also reported a significant abstention from tobacco at 
three months post treatment. Finally, a pilot study by Martino, Carroll, Nich, and 
Rounsaville, (2006) reported a significant reduction in cocaine use at three months post 
treatment, but a non-significant reduction in cannabis use compared to the control 
condition. However, participants were reported to have high levels of motivation at 
baseline, suggesting a possible ceiling effect, which may have served to reduce any of the 
potential benefits from the motivational based approach. Two studies (Martino et al., 2006; 
Baker et al., 2006b) measured the impact of the motivational based approach on other 
outcomes, specifically mental health symptoms and general functioning, but neither 
reported a significant effect.  
 
A number of methodological limitations are apparent. With the exception of one study 
(Baker et al., 2006a), all of the above studies used a small number of participants which 
increases the possibility that the results reported were due to chance. Neither Kisely et al. 
(2006) nor Baker et al. (2006a) controlled for the effect of therapists’ time, therefore the 
outcome may be due to additional therapist time rather than the intervention per se. 
Significant rates of attrition of (50%) were reported by Ziedonis et al. (1997) and Kisely et 
al. (2006). This attrition highlights the general difficulty of engaging people with SMH 
problems in clinical interventions (Drake & Mueser, 2000) and may also over-estimate the 
efficacy of the intervention by not including the outcomes of those participants that are 
more difficult to engage. It is not possible to accurately predict the impact of these 
  
methodological issues on the outcomes of these studies, although the evidence does appear 
consistent in that motivational based approaches are effective in reducing tobacco, alcohol, 
cocaine and that these effects are often maintained between three to six months after end of 
treatment. 
 
Four studies reported an increase in substance use following the motivational based 
approach however this was not significantly greater than that observed in the control 
condition. The evidence indicates non-significant reduction for alcohol and amphetamines 
but the evidence for cannabis is less consistent. Two studies did not report a reduction in 
cannabis use (Baker et al., 2002; Teeson, 1999) but reported a non-significant reduction in 
alcohol and amphetamines which subsequently reduced at three months (Baker et al., 
2002) and alcohol and tobacco (Teeson, 1999). Whereas two studies reported a reduction 
in cannabis that diminished after three months (although there was a significant reduction 
in amphetamines at twelve months) (Baker, Bucci, Lewin, Kay- Lambkin, Constable, & 
Carr, 2006b) and was also maintained at six months amongst participants with first episode 
psychosis (Edwards Elkins, Hinton, Harrigan, Donovan, Athanasopolous & McGorry, 
2006). Only one study reported outcomes in addition to changes in substance use. Baker et 
al. (2006b) reported a significant increase in general functioning at twelve months and a 
reduction in rates of depression at end of treatment which subsequently declined at three 
months, but with no change in substance dependence. In contrast, four studies (Baker et al., 
2002; Teeson, 1999; Edwards et al., 2006; Martino et al., 2006) did not report any 
significant change in general functioning, motivation or symptomatology.  
 
There are a number of methodological differences between studies that did not report a 
significant change in substance use compared to the control group. Three studies (Baker et 
al., 2002; Edwards et al., 2006; Martino et al.,2006) all reported high levels of motivation 
at baseline, especially amongst cannabis users in their sample (Martino et al., 2006; Baker 
et al., 2006). There is evidence that motivational based approaches are more effective with 
individuals who have the lowest levels of motivation pre-treatment, but are less effective 
with those in a higher motivational state (Colby, Monti, Barnett, Rohsenow, Weissman, & 
Spirito, 1998). Therefore a ‘ceiling effect’ may have been operating, which may have 
limited the effect of the motivational based approach. Baker et al. (2002); Edwards et al. 
  
(2006) and Martino et al. (2006) were the only studies to have used a more active 
intervention in the control condition (for example psycho-education) rather than treatment 
as usual. When motivational based approaches have been compared with other active 
treatments in the general substance using population, there is a trend for them to have not 
reported significant reduction in substance use (Hettema et al., 2005). A similar pattern 
could be operating in the studies by Baker et al. (2002); Edwards et al. (2006) and Martino 
et al. (2006). An alternative explanation may be that when baseline levels of motivation are 
already high at baseline and a ceiling effect is present, then other more directive 
interventions (for example psycho-education or advice) may be equally effective in 
bringing about change.  
 
 
Summary 
There is evidence that motivational based approaches were effective for alcohol, 
amphetamines and tobacco. There are a number of methodological limitations that require 
these outcomes to be treated with caution, for example: small sample sizes, high attrition 
and not controlling for the additional therapist time. When measured over time, the effect 
appears to decline. The evidence for the efficacy upon cannabis use is less consistent 
(Edwards et al., 2006; Baker et al., 2002; Martino et al., 2006), however, these studies also 
reported high levels of motivation at baseline. Individuals who present with initially lower 
levels of motivation to change typically respond better to motivational based approaches 
than those with higher levels of baseline motivation (Heather, Rollnick, Bell & 
Rischmond, 1996). This may have produced a ‘ceiling effect’. These three studies also 
included more active interventions in their control condition (for example, psycho-
education). More active interventions may therefore be more suitable for individuals who 
have higher levels of motivation, but less suitable for individuals with lower levels of 
motivation. It is therefore uncertain if the effect of the motivational based approach was 
less effective upon cannabis or whether the efficacy of the motivational approach was 
limited by the presence of a ‘ceiling effect’ and the more active control condition. The vast 
majority of studies did not report any significant change in mental health symptomatology, 
general functioning or substance dependence.    
 
 
 
Table 4: Decreasing behaviours (substance specific)  
 
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
 
Therapy fidelity 
 
Experienced 
MH 
professionals 
 
Sample 
 
Diagnosis 
 
Context  
 
Control 
 
Controlled 
for therapist 
time  
Attrition 
 
Single 
blinding 
Primary 
Measures 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 0.05 
Graeber et al 2003 
 
A pilot study 
comparing 
motivational 
interviewing and an 
educational 
intervention in 
patients with 
schizophrenia and 
alcohol use 
disorders 
 
Pilot 
 
MI 
 
3 x 1hr 
 
None 
 
 
Alcohol only 
Manualised 
 
No fidelity to 
treatment  
 
MH 
professionals 
Schizophrenia 
100% 
 
Study n=15 
Control n=15 
 
Outpatient 
 
Psycho-
education 
 
(Therapist 
time not 
controlled 
for) 
9% 
 
Not blind 
assessor 
Abstinence  
 
Number of days 
drinking. (BDP)  
 
Drinking 
Intensity (BDP) 
 
Consumption 
(BDP) 
 
 
1,2,6 months 
A significant reduction for 
frequency of drinking days 
and days abstinence 
 
 
Non significant  
 
 
Non significant  
 
 
 
 
Baker et al (2006a) 
 
A randomised 
controlled trial of a 
smoking cessation 
intervention among 
people with 
psychotic disorder 
 
RCT 
MI + CBT + Nicotine 
replacement therapy  
 
8 x 1 hr  
 
 
Tobacco 
 
 
 
 
Manualised 
 
 
Fidelity to 
treatment  
 
 
Trained therapist 
57% schizophrenia 
spectrum 
 
Study n= 147 
Control n= 151 
 
Routine care 
 
 
(not 
controlled 
for therapist 
time) 
Not stated 
 
Single 
blind 
Abstinence/ 
Reduction  
(breathalyser test) 
 
Symptoms 
BPRS, BDI, 
STAI 
 
Functioning  
SFS 12 
 
Significant reduction at all 
follow up points, non 
significant abstention  
(but only for the 50% 
completing all 8 sessions) 
 
Non-significant 
 
 
 
Non significant 
 
 
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
 
Therapy fidelity 
 
Experienced 
MH 
professionals 
 
Sample 
 
Diagnosis 
 
Context  
 
Control 
 
Controlled 
for therapist 
time  
Attrition 
 
Single 
blinding 
Primary 
Measures 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 0.05 
3,6,12 months 
 
Kisely et al  2006 
A group 
intervention which 
helps people with 
dual diagnosis 
reduce their tobacco 
use 
 
Pilot 
 
MI + CBT + Nicotine 
replacement therapy 
 
10 week 
 
Tobacco 
Manualised 
 
Trained 
therapists 
Schizophrenia 40% 
Affective disorder 
40% 
 
 
Study n=19 
Waiting list 
control 
 
Not 
controlled 
for therapist 
time 
50% 
 
 
Single 
Blind 
Tobacco use  
TLFB 
 
 
 
3 months 
Significant tobacco  abstention 
Ziedonis et al 
(1997) 
 
Schizophrenia and 
Nicotine Use: 
Report of a pilot 
smoking cessation 
program 
 
Pilot 
 
 
 
Nicotine replacement + 
Motivational 
enhancement + 
behavioural therapy 
 
10 week 
 
Tobacco 
Not stated 
 
Trained 
therapists 
Schizophrenia 
spectrum 100% 
 
Study n=24 
No control 50% 
 
N/A 
Reduction  
 
 
Abstention 
 
 
 
 
6 months 
40% decreased consumption 
by 50% 
 
13% remained abstinent for at 
least 6 months 
 
 
 
       
 
 
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
 
Therapy fidelity 
 
Experienced 
MH 
professionals 
 
Sample 
 
Diagnosis 
 
Context  
 
Control 
 
Controlled 
for therapist 
time  
Attrition 
 
Single 
blinding 
Primary 
Measures 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 0.05 
 
 
 
 
Martino et al (2006) 
 
 
A randomised 
controlled pilot 
study of 
motivational  
interviewing for 
patients with 
psychotic and drug 
use disorders 
 
PILOT 
 
 
 
MI  
 
2 x 1 hr 
 
Alcohol  
Cocaine  
Cannabis  
 
 
Manualised  
 
 
 
Fidelity to 
treatment  
 
MH 
professionals 
 
 
 
Schizophrenia 
spectrum 77% 
Psychosis 23% 
 
 
Study n=24 
Control n=20 
 
Outpatient  
 
Psychiatric 
interview 
2 x 1 hr   
 
Controlled 
for therapist 
time 
 
23% 
 
 
 
Yes 
 
Functioning 
GAS, BDI 
 
Symptoms 
PANSS 
 
Substance use: 
TLFB, 
Urinanalysis 
 
1,2,3 months  
Non-significant Improvement  
 
 
Non-significant improvement  
 
 
Significant reduction for 
cocaine but non significant   
reduction for cannabis. Non 
significant poly-drug change.    
Baker et al   (2002) 
 
Evaluation of a 
motivational 
interview for 
substance use within 
psychiatric in-
patient services 
MI  + CBT 
 
30-45 mins 
 
Alcohol 
cannabis  
amphetamines  
 
Manualised,  
 
 
No fidelity 
check 
 
 
Undergraduates , 
Schizophrenia 38% 
Affective 29% 
Other 34% 
 
Study n=43 
Control n=46 
 
Inpatient 
Advice  
 
30-45 mins 
 
Controlled 
for therapist 
time 
45% 
 
 
Blind 
Substance use 
OTI 
 
 
Symptoms 
BSI 
 
3, 6,12 months 
A non-significant 
improvement in alcohol and 
amphetamines but not for 
cannabis. Diminished after 3 
months. 
 
 
 
 
 
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
 
Therapy fidelity 
 
Experienced 
MH 
professionals 
 
Sample 
 
Diagnosis 
 
Context  
 
Control 
 
Controlled 
for therapist 
time  
Attrition 
 
Single 
blinding 
Primary 
Measures 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 0.05 
 
RCT 
 
 
 
trained and 
supervised 
 
 
 
 
 
 
Baker et al (2006b) 
 
Cognitive 
Behavioural 
Therapy for 
substance use 
disorders in people 
with psychotic 
disorders 
 
RCT 
MI +  CBT  
10 x 30-60 min   
 
Alcohol  
cannabis  
amphetamines 
 
 
Manualised,  
 
 
Yes fidelity 
check  
 
 
MH 
professionals 
Schizophrenia 62.2 
% 
 
Schizoaffective 
12.2%  
Bipolar 9.2 % 
Other psychoses 
16% 
 
Study n= 65 
Control n=65 
 
Outpatient 
TAU +  
assessment + 
self help 
material 
 
(No control 
for therapist 
time) 
27% 
 
 
 
Blind  
Substance use 
OTI 
 
Symptoms: 
BPRS, BDI 
 
Motivation: 
RTCQ 
 
Dependence 
SCID 
 
Functioning 
GAF 
3,6 12 months  
 
 
Non-significant improvement 
for study group in cannabis 
use and depression at 3 
months only. Non-significant 
improvement 
amphetamines  
 
 
 
Non significant improvement 
at 12 months 
Edwards et al 2006 
 
Randomised 
controlled trial of a 
cannabis-focused 
 CBT+ MI  
 
10 x 30-60min   
 
Booster 3 months at 
Manualised 
 
No fidelity 
treatment 
 
Schizophrenia 72%; 
Affective psychosis 
11% 
Other 17% 
 
Psycho-
education 
 
Controlled 
for therapists 
Not stated  
 
Single 
blind 
Cannabis use 
CASUAS 
 
Symptoms-BPRS 
 
Reduction in cannabis for both 
groups and sustained at 6 
months. 
 
Non-significant reduction for 
 
  
Author / Title Intervention   
Duration  
 
Substance(s) 
 
 
 
Therapy fidelity 
 
Experienced 
MH 
professionals 
 
Sample 
 
Diagnosis 
 
Context  
 
Control 
 
Controlled 
for therapist 
time  
Attrition 
 
Single 
blinding 
Primary 
Measures 
 
 
Follow up 
period(s) 
 
Outcome 
 
Effect  significance at p< 0.05 
intervention for 
young people with 
first episode 
psychosis 
 
RCT 
end 
 
 
Cannabis only 
MH 
professionals 
 
 
Study = 23 
Control n= 24 
 
Outpatient  
 
time  
Functioning-
SOFAS 
 
Motivation-
RTCQ 
 
0, 6 months 
study group over control 
 
Non-significant  
 
Non-significant  
 
Non-significant motivational 
change  
Teeson et al 
1999 
 
Evaluation of a 
treatment 
programme for 
serious mental 
illness and 
substance use in an 
inner city area 
 
Case study 
MI + relapse prevention 
 
Duration not specified 
 
Alcohol  
Cannabis  
Tobacco 
Not stated 
 
Not stated 
 
Not stated 
Schizophrenia 67% 
Bipolar 11% 
Anxiety 11% 
Depression 8%  
PD 3% 
 
Study n=67 
 
Outpatient 
No control 45% 
 
N/A 
Symptomatology- 
GHQ 
BPRS 
 
Substance use 
OTI 
 
 
12 months 
Non-significant  
Non-significant  
 
 
Non-significant  
 
 
BDI- Beck Depression Inventory; BPRS- Brief Psychiatric Rating Scale; CASUAS- Cannabis and substance use assessment schedule; GAF- Global Assessment of 
Functioning; GAS- Global Assessment Scale; GHQ-General Health Questionnaire; PANSS –Positive and Negative Symptom Scale; RTCQ-Readiness to change 
questionnaire; SCID- Structured Clinical Interview for DSM-IV; SFS 12 – Short Form Survey 12 item; SOFAS- The social and occupational functioning scale; STAI- State 
trait anxiety inventory; TLFB-Time Line follow back. 
 
 
 
  
 
Section 3: Considering the evidence, are motivational based approaches supported 
with this group? 
 
The evidence supporting the efficacy of motivational based approaches in increasing 
adherence to medication was inconsistent. A minority of studies reported either an increase 
in adherence to medication (Kemp et al., 1998), or a cognitive change and/or a change in 
psychotic symptoms (Tay, 2007;Maneesakorn et al., 2007). However, the duration of effect 
declined over time. Two good quality randomised controlled trials (RCTs) (Gray et al., 
2006; O’Donnell et al., 2003) implemented lengthy outcome periods. Therefore any short 
term effects present could not have been captured and could not corroborate the outcomes 
from the studies that reported an increase in medication adherence. Few studies aimed to 
increase treatment retention; however outcomes were more consistent, with the majority of 
studies reporting an increase in treatment attendance. Duration of outcome was also brief 
and rarely measured attendance beyond the first appointment.  
 
The majority of studies that aimed to reduce ‘unhealthy’ behaviours reported a reduction in 
poly-drug use as well as studies reporting reductions in specific substances notably 
alcohol, tobacco and amphetamine use. The evidence for cannabis was less consistent. A 
number of other positive outcomes from the motivational based approaches were reported; 
reductions in levels of substance dependence, improvements in general functioning and 
reduced mental health symptomatology. However these outcomes were reported less 
consistently by the varying studies. A majority of studies that measured the duration of 
effect beyond the end of treatment reported a decline over time. This is an effect reported 
from motivational based approaches used in the general substance using population 
(Hettema et al., 2005). Duration of effect could not be reviewed consistently because 
studies were inconsistent in their use of follow up periods. 
  
A number of methodological limitations require these results to be treated with caution, 
notably, small sample sizes and a lack of control for the additional therapist attention that 
resulted from the motivational based approach. When motivational based approaches have 
been compared with other more active treatments in the control condition as opposed  to 
less active controls such as treatment as usual (e.g. Edwards et al., 2006; Baker et al., 2002;  
  
Martino et al., 2006) there was a trend for them to have not reported significant reduction 
in substance use. This was a pattern observed in the general substance using population 
(Hettema et al., 2005). Therefore more directive interventions such as psycho-education 
may be equally effective. There is a trend for studies that do not report a significant change 
in behaviour following the motivational based approach to also report high levels of 
baseline motivation. This is apparent amongst the medication adherence studies (e.g. Gray 
et al., 2006; Byerly et al., 2005) and amongst the substance reduction studies (e.g. Edwards 
et al., 2006; Baker et al., 2002; Martino et al., 2006). When baseline levels of motivation 
were high, more directive interventions e.g. advice or psycho-education, may be as at least 
effective. This suggests the use of a stepped care approach to intervention. Studies did not 
report baseline motivational levels consistently; therefore this could not be explored further 
in the present review.  
 
Despite these limitations it is my opinion that motivational based approaches were 
effective with individuals with severe mental health problems. This was most evident in 
reducing substance use quantity and frequency behaviours and increasing treatment 
retention. Given there was a pattern of the effect from the motivational approach to 
diminish over time, it is recommended that when motivational based approaches are used, 
there is ongoing repetition through the use of booster sessions, with the intention of 
maintaining that effect.  
  
 
 
 
 
 
 
 
 
 
 
 
  
Section 4: The way forward 
 
Replication of research findings is considered to be at the heart of science. With the 
exception of compliance therapy (Kemp et al., 1998), no other motivational based 
approach has been repeatedly tested for efficacy. Replication of treatment effects is a 
priority for future research. 
 
I suggest that future research aims to control for the effect of the motivational intervention 
by comparing one intervention consisting of an integrated psychosocial intervention which 
includes motivational interviewing with the same integrated intervention which does not 
include motivational interviewing, thereby controlling for the presence of the motivational 
intervention. Motivational interviewing is considered as most helpful in the early stages of 
working with dually diagnosed clients (Barrowclough, Haddock, Fitzsimmons & Johnson, 
2006), therefore in such a comparative study the motivational intervention should be 
administered first. Booster sessions should be regularly incorporated and to measure 
whether the effect is maintained.  
 
I suggest that future designs recruit a sufficiently large sample of participants with a 
variety of severe mental health diagnoses so that sub-analyses by diagnosis, and by 
baseline levels of motivation and substances used, can be performed. Behavioural 
measures should be the primary outcome, measuring frequency, intensity and quantity of 
change. Additional measures should include changes in stages of change symptoms, 
symptomatology, substance dependence and global measures of functioning. This research 
should seek to explore how varying baseline levels of substance use and type, dependence, 
and motivation all interact to mediate the efficacy of motivational based approaches upon 
increasing ‘helpful’ behaviour and decreasing ‘unhelpful’ behaviours. Outcomes should be 
measured immediately after intervention and then at monthly intervals to plot duration of 
the treatment effect.  
 
The suggestions for future research designs outlined above should aim to contribute to a 
number of issues. Rather than asking whether motivational based approaches are effective 
for individuals with SMH problems, I suggest that the question is: i) what contribution 
  
does the motivational interview make to the integrated intervention, ii) are motivational 
based approaches more effective for those with low rates of motivation at baseline, iii) are 
other more direct interventions as effective when baseline motivation is high at baseline, 
and iv) and for how long are motivational based approaches are effective.  
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Abstract 
 
 
The present study examined reasons for cannabis use amongst individuals with and without 
severe mental health problems. Participants (N=42) included cannabis users with severe 
mental health problems (N=18) and cannabis users without severe mental health problems 
(N=23). All participants were interviewed about motives and expectancies of the effects 
from using cannabis. Findings from the present study were that individuals with severe 
mental health (SMH) problems did not differ from those without mental health problems in 
terms of motives for using cannabis;  they use for coping, enhancement and social reasons. 
However individuals with SMH problems differed in that they expected cannabis to be 
more ‘socially and sexually facilitative’. The finding from the qualitative component of the 
study indicated that only a small minority of individuals with SMH problems used 
cannabis to help with symptoms of their SMH problem or side effects of medication. 
Irrespective of mental health status, participants who used cannabis more problematically 
endorsed more coping and enhancement motives. Interventions aimed at reducing sources 
of distress, developing more adaptive ways of coping, together with treatments aimed at 
reducing the limitations for obtaining pleasure may be helpful in reducing enhancement 
and coping motives amongst more problematic cannabis users with SMH problems.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Introduction 
 
 
Problems associated with cannabis use amongst individuals with severe mental health 
problems 
There is good evidence to suggest that individuals who have severe mental health (SMH) 
problems (that is, difficulties that lie on the schizophrenia spectrum) and use cannabis have 
poorer treatment outcomes than their non-cannabis using counterparts and even relatively 
minor use can be predictive of poor outcome (for example, Van Os, Bak, Hanssen, Bijl, De 
Graaf & Verdoux, 2002; Caspari, 1999; Buhler, Hambrecht, Loffler, Van der Heiden & 
Hafner, 2002). Cannabis is recognised as a drug that when used by people with severe 
mental health problems may: increase the risk of depression (Patton, Coffey, Carlin, 
Degenhardt, Lynskey & Hall, 2002); increase psychotic symptoms (for example, Semple, 
Mcintosh & Lawrie, 2005; Arseneault, Cannon, Witton & Murray, 2004; Degenhardt, Hall 
& Lynskey, 2003; Linszen, Dingemans & Lenior, 1994); exacerbate cognitive impairment 
and medication side effects (for example, D’Sousa, Abi-Saab, Madonick, Forselius-Bielen, 
Doesrch, Braley, Gueorguieva, Cooper & Krystal, 2005) and is associated with increased 
relapses and hospitalisations (Barrowclough, Haddock, Fitzsimmons & Johnson, 2006).  
 
Dixon, Haas, Weiden, Sweeney and Frances, (1990) defined the clinical problem as 
continued cannabis use frequently exacerbates severe mental health problems, yet many 
individuals with a SMH problem also derive beneficial effects from cannabis and continue 
to use it. Epidemiological studies have consistently reported a higher prevalence of 
cannabis use and misuse in people with severe mental health (SMH) problems compared to 
the general population (Mueser, Yarnold, Levinson, Singh, Bellack, Kee, Morrison & 
Yadalam, 1990). Estimates of prevalence based upon data from 53 studies of treatment 
samples suggest that lifetime cannabis use and abuse rates amongst people with severe 
mental health problems are 42.1% and 22.5% respectively. Estimates for current use and 
current misuse are 23.0% and 11.3% respectively (Green, Young & Kavanagh, 2005). A 
number of methodological variations are likely to have contributed to the range in 
estimates present in the prevalence literature, notably: sample sizes, participant selection, 
  
diagnostic criteria, definitions of abuse / dependence and changes in patterns of cannabis 
use over time (Fowler, Carr, Carter & Lewin, 1998).  
 
A recent review of treatments for substance use reduction amongst individuals with SMH 
problems (Cleary, Hunt, Matheson & Walter, 2008), indicated that motivational 
interviewing (Miller & Rollnick, 2002) is the most empirically supported intervention. 
Motivational approaches involve exploring people’s motives for using substances and/ or 
their expectations of what substance use will achieve (Spencer, Castle & Michie, 2002). 
An understanding of self-reported expectancies and motives that people are consciously 
aware of is required in order to inform treatment approaches (Graham, 1998).  The next 
section introduces a motivational model of alcohol use. This motivational model aims to 
utilise self-reported expectancies and motives that people are consciously aware in order to 
help understand why the general population continue to use alcohol problematically. 
Subsequently, this motivational model will be applied to help understand why cannabis is 
continuously used within the SMH population. 
 
The motivational model  
An empirically based model of alcohol use by Cox and Klinger (1988) incorporates 
expectations of the effects of alcohol and motives for using alcohol into its conceptual 
framework. This model may have been overlooked in explaining reasons for continued 
cannabis use amongst individuals with severe mental health problems (Spencer et al., 
2002). The motivational model posits that individuals are motivated to use alcohol based 
on the desire to achieve a particular emotional effect, rather than being driven solely by the 
direct chemical effects or the avoidance of any symptoms of withdrawal. A range of 
factors may play a part in the likelihood of alcohol being used to achieve such a desired 
emotional effect: biochemical reactivity (for example, the ability to metabolise alcohol 
efficiently); personality characteristics (for example, nonconformity or impulsivity traits); 
environmental influences (for example, cultural acceptability and family/ peer attitudes), 
and current contextual factors (for example, availability), however it is argued by Cox and 
Klinger (1988) that the final decision to use alcohol is mediated by cognitive processes.  
For an individual to use alcohol, first they must have the expectation that using alcohol will 
achieve a particular emotional effect (cognitive element) and second, the individual must 
  
also place a positive value on achieving this emotional effect; that is they must be 
motivated. Expectancies and motives are distinct conceptually; expectancies are thought to 
be more distal to substance use behaviour and motives more proximate (Cooper, 1994). 
The next section will define these concepts more distinctly.  
 
Drug use expectancies 
Drug use expectancies are beliefs that an individual holds about the expected effects from 
using a drug. These beliefs can be derived from a combination of factors, notably: 
environmental and cultural influences; interactions with peers; and previous experiences of 
use (Schafer & Brown, 1991). In terms of influencing substance use behaviour, the 
congruence of the expected effect with the actual effect is considered to be of minimal 
significance, rather it is the endorsement of the expected effect that is definitive (Jones, 
Corbin & Fromme, 2001).  It is anticipated that expectations of highly valued outcome 
(positive expectancies) would increase the probability of cannabis being used, and 
expectations of undesirable outcomes (negative expectancies) would decrease it (Green, 
Kavanagh & Young, 2007). Statistically significant associations between cannabis 
expectancies and patterns of cannabis use have been reported within in-patient substance 
treatment (Galen & Henderson, 1992), college students (Schafer & Brown, 1991) and 
adolescents (Aarons, Brown, Stice & Coe, 2001). In general, less problematic cannabis 
users expected more negative effects from using cannabis which include: ‘global negative 
effects’ and ‘cognitive and behavioural impairment’. In contrast, more problematic 
cannabis users reported lower expectations of negative effects and greater expectations of 
positive effects which include: ‘relaxation and tension reduction’; ‘social and sexual 
facilitation’; and ‘perceptual and cognitive enhancement’ (Aarons et al., 2001).  
 
Deficits in more constructive coping mechanisms and positive expectancies about 
substance use operate to jointly promote the use of a drug as a coping strategy (Cooper et 
al., 1988). Problematic substance users are therefore considered to diverge from non-
problematic users in their capacity to cope with everyday stressors and in their 
expectations of a substance as being facilitative (Abrams & Niaura, 1987). From a clinical 
intervention perspective, drug use expectancies, both positive and negative, are maintained 
despite incongruence with actual effects. Increasing congruence between expected and 
  
actual effects may reduce the likelihood of cannabis being viewed as facilitative (Hayaki, 
Anderson & Stein, 2008). This may reduce the likelihood of cannabis being used and serve 
to reduce the risk of relapse of SMH symptoms.  
 
 
Drug motives 
Whilst an individual must hold a particular expectancy that a desired emotional effect will 
be achieved before a substance is consumed, they must also be motivated to achieve this 
specific emotional effect (Leigh, 1990). Cooper, Russell, Skinner and Windle (1992) 
adapted and developed the motivational model (Cox & Klinger 1988) and introduced the 
concept of three different motives for using alcohol. These are: Enhancement motives; 
Coping motives and Social motives. Enhancement motives are defined as the desire to use 
a substance to experience a particular emotional state rather than modify a pre-existing 
negative emotional state (e.g. to get high, to have fun; Cooper, Krull, Agocha, Flanagan, 
Grabe, Orcutt, Jackson & Dermen, 2008). In contrast, coping motives are defined as using 
a substance to attempt to minimise negative affect and thought to involve a more reactive 
response precipitated by a negative emotional experience. Coping motives are thought to 
be more prevalent amongst individuals susceptible to experiencing high levels of negative 
emotions (Cooper, Frone, Russell & Mudar, 1995). Social motives are defined as substance 
use primarily for social reasons thereby engaging in customary or normative behaviour 
(e.g. something to do with friends; Cooper et al., 2008). 
 
Enhancement, Coping and Social motives for drinking are measured in the Drinking 
Motives Questionnaire (DMQ) (Cooper et al., 1992), outcomes from which indicate that 
using alcohol to cope is more strongly predictive of heavier and solitary alcohol use and 
dependence (Cooper et al., 1995). Increased dependence may be understood in the context 
that individuals using for coping motives are less capable of exercising volitional control 
over precipitating factors (Cooper et al., 1992). In contrast, mood states, either positive or 
negative, do not directly predict drinking for enhancement motives (Cooper et al., 1995). 
Enhancement motives are more likely to be related to relatively heavier, more sporadic 
periods of drinking, i.e. drinking to intoxication within a social context (Cooper, 1994), but 
are less likely to be directly related to problematic alcohol use (Cooper, 1994). Social 
  
motives are associated with moderate drinking in a social context and are unlikely to be 
related to problematic use (Cooper, 1994). Given the empirical support for the motivational 
model of alcohol use, it is thought that this model has been somewhat overlooked when 
examining cannabis use amongst individuals with SMH problems (Spencer et al., 2002). 
The next section will summarise research that has been conducted on cannabis use 
amongst individuals with SMH problems. 
 
Research on cannabis use amongst individuals with severe mental health problems 
Research investigating cannabis use amongst individuals with SMH problems has tended 
to examine self-reported reasons for using cannabis (e.g. Addington & Duchak, 1997; 
Fowler, Carr, Carter & Lewin, 1998; Goswami, Singh, Mattoo & Basu, 2003; Schofield, 
Tennant, Nash, Degenhardt, Cornish, Hobbs & Brennan, 2006) or reasons for using a 
variety of different substances, of which cannabis was one (e.g. Test, Wallisch, Allness & 
Ripp, 1989; Dixon, Haas, Weiden, Sweeney & Frances, 1991; Warner, Taylor, Wright, 
Sloat, Springett, Arnold & Weinberg 1994; Baigent, Holme & Hafner, 1995;  Gearon, 
Bellack, Rachbeisel & Dixon, 2001). The methodologies utilised in the above studies 
either asked participants open-ended questions about their reasons for using cannabis, or 
participants were asked to select reasons from predetermined lists. A recent review of this 
literature (Dekker, Linzen & de Haan, 2009) reported that regardless of the methodology 
used, the majority of the self-reported reasons can be categorised in to three main groups: 
enhancement motives, motives to cope with negative emotional affect, and social motives. 
A minority of participants reported using cannabis to relieve symptoms and medication 
side effects stemming from SMH problems (e.g. “to decrease voices, to decrease 
hallucinations” Addington et al., 1997; Schofield et al., 2006). I suggest that the three main 
motives reported by Dekker et al., 2009 correspond closely with the three motives implicit 
to the motivational model (Cooper et al., 1992), and can be measured by an adapted 
version of the DMQ (Cooper et al., 1992) and the Drug Use Motives Measure DUMM 
(Meuser et al., 1995).  
 
Numerous studies have also provided qualitative data on the subjective expectations from 
using cannabis (Green et al., 2007; Dixon et al., 1991; Addington et al., 1997; Goswami et 
al., 2003; Baigent et al., 1995; Schofield et al., 2006). Outcomes from these studies 
  
indicated that positive expectations of effects on mood, anxiety, relaxation, energy and 
socialisation were reported together with a number of negative expectancies (Dekker et al., 
2009). These expectations correspond to many of the items on the Marijuana Effect 
Expectancy Questionnaire, a scale designed to measure the expected effects from using 
cannabis and validated amongst individuals with SMH problems (Schafer & Brown, 1991).  
    
Two studies to date have applied the motivational model to substance use amongst 
individuals with SMH and have used standardised measures to examine motives and 
expectancies problems. The first, Mueser, Nishith, Tracy, DeGirolamo and Molinaro 
(1995) assessed expectancies and motives amongst 70 inpatients and outpatients with SMH 
problems who used variable quantities of a range of different substances. Motives were 
measured by the Drug Use Motives Measure (DUMM). Cannabis expectancies were 
measured using the Marijuana Effect Expectancy Questionnaire (MEEQ). The outcomes 
suggested that coping and enhancement motives (but not social motives) were more 
strongly associated with drug-related difficulties. The study also found that a history of / or 
recent drug abuse was associated with increased endorsement of ‘social and sexual 
facilitation’ and ‘perceptual and cognitive enhancement’, both of which are positive 
expectancy domains. The second study (Spencer et al., 2002) interviewed 69 participants 
with SMH diagnoses and assessed the motives for using a range of substances using the 
Drug Motives Questionnaire (DMQ). They also found that coping and enhancement 
motives, but not social motives, were associated with substance dependence. A low 
endorsement of an additional motive ‘to relieve positive symptoms and medication side 
effects’ was also reported, but this was not associated with substance dependence. 
Evidence that coping and enhancement motives for substance use were associated with 
levels of dependence provides support for the proposition that substance use amongst 
individuals with SMH problems can be understood using the motivational model.  
  
A strength of the studies by Mueser et al. (1995) and Spencer et al. (2002) is that unlike 
previous work in this area, they employed standardised measures. However a limitation 
was that they did not employ a comparison group, a criticism applicable to several studies 
investigating reasons for substance use amongst SMH samples (e.g. Dixon et al., 1991; 
Fowler et al., 1998; Fowler et al., 1998) stated that direct comparison of outcomes with 
  
studies that use general population samples is potentially misleading since the 
demographic characteristics of the two groups may differ substantially. To this end, Fowler 
et al. (1998) suggested the employment of a comparison group which would normally 
consist of ‘young to middle aged, predominantly male, single, unemployed persons’. Two 
studies to date have incorporated an appropriate comparison group (Green, Kavanagh & 
Young, 2004; Schaub, Fanghaenel & Stohler, 2008). Green et al. (2004) used a qualitative 
self report methodology and found that participants with psychosis were more likely to use 
cannabis to cope with negative affective states and reduce boredom. They concluded that 
interventions may need to address poverty of reinforcement and reduce social exclusion 
and increase social activity. Schaub et al. (2008) implemented a quantitative methodology 
(an non-standardised list of motives) and reported that participants with schizophrenia 
were more likely to use cannabis to reduce boredom. A limitation of these two studies was 
that they did not utilise standardised measures.  
 
 
Present study  
The present study aimed to address the limitations of studies that either have not used a 
comparison group (Mueser et al., 1995; Spencer et al., 2002) or have not used standardised 
measures (Green et al., 2004; Schaub et al., 2008) and aimed to contribute to the 
understanding of what drives individuals with SMH to continue to use cannabis by directly 
comparing motives and expectancies amongst cannabis users with and without SMH 
problems.  
 
To compare the motives and outcome expectancies amongst cannabis users with and 
without SMH problems, the present study recruited two groups who both used comparable 
quantities of cannabis, the first group were diagnosed with SMH problems (SMH group); 
the second group were not diagnosed with SMH problems (non-SMH group). The study 
measured and compared the expectancies and motives for using cannabis reported by 
participants in the two groups, using standardised measures.  
 
The cannabis motives measure (DUMM) does not assess for motives related to helping 
with SMH symptoms or SMH medication side effects. However studies have reported a 
  
small proportion of individuals with SMH problems report motives concerning medication 
side effects or to help with the SMH symptoms directly (for example: Warner et al., 1994; 
Fowler et al., 1998). The present study therefore included an additional qualitative 
component to enable participants to report any additional motives that were either related 
to the experience of having a SMH or additional motives that were not already included in 
the DUMM. 
 
The second aim of the study was to compare the motives and expectancies of (i) high 
dependent and low dependent cannabis users and (ii) high use and low use cannabis users. 
To achieve this, all participants regardless of mental health status were allocated into either 
high or low groups using a ‘median split’ technique. 
 
 
Hypotheses 
The primary hypothesis was that there would be no difference between the SMH and the 
non-SMH group on measures of motives or endorsement of negative and positive 
expectancies from using cannabis. The primary hypothesis is therefore expressed in the 
null form. 
 
The secondary hypothesis was that regardless of mental health status, participants who 
were categorised into high cannabis usage and participants categorised into high cannabis 
dependence would endorse more coping and enhancement motives, more positive 
expectancies and less negative expectancies compared to their low usage and low 
dependent counterparts.   
 
 
 
 
 
 
 
 
  
Method 
 
 
Sampling and participants  
Two groups were recruited for the current study. The first group included participants 
(N=18) with a diagnosis of severe mental health problems (SMH group) and who recently 
used cannabis. All participants in the SMH group were recruited between 2009 and 2010. 
Participants were recruited through four Assertive Outreach Teams (AOT) located within 
Birmingham and Solihull Mental Health Foundation Trust and three AOTs located within 
Coventry and Warwickshire NHS Trust. AOTs provide intensive support for service-users 
with SMH problems who are 'difficult to engage' within traditional community mental 
health teams. Intensive input is available from the service to sustain engagement with care 
and support offered at times suited to the service user either in their home or other 
community setting. Support from the service is not time-limited and is often provided for 
years rather than months (Bond, 1991).  
 
The second group consisted of participants (N=23) without SMH problems (non-SMH 
group). Participants in the comparison group were recruited from a substance misuse 
service located within Birmingham and Solihull Mental Health Found NHS Trust between 
2009 and 2010. The substance misuse service was predominantly orientated towards 
supporting individuals with both past and current heroin-use difficulties, although 
individuals with other alcohol and drug difficulties were also supported. Service users 
attended the service in an outpatient setting and engaged in harm reduction interventions. 
The vast majority of service users would not be diagnosed with a severe mental health 
problem, consequently this service was considered an appropriate source from where to 
recruit a comparable sample of cannabis users who did not have SMH problems.  
 
Ethical approval for the study was granted by the Local Research Ethics committee 
(Appendix A). Research and development approval was granted by the appropriate NHS 
Trusts (Appendix A) 
 
 
  
Severe mental health group inclusion criteria 
To be included in the SMH group participants had to meet the following criteria:  
i) to be a user of the assertive outreach team service; ii) to have a diagnosis of a severe 
mental health problem (i.e. a diagnosis on the schizophrenia spectrum); iii) to have used 
cannabis at least once within the previous month.  Non-severe mental health diagnoses (for 
example: depression, anxiety) or diagnoses related to substance use were not criteria for 
exclusion. Participants who displayed acute psychotic symptoms or signs of acute 
intoxication at the time of assessment were excluded. 
 
Non-severe mental health group inclusion criteria 
To be included in the non SMH group potential, participants had to meet the following 
criteria: i) to be a user of the substance misuse service; ii) to not have a diagnosis of a 
severe mental health problem and iii) to have used cannabis at least once within the last 
month. Non-severe mental health diagnoses (for example: depression, anxiety) or 
diagnoses related to substance use or the use of other substances were not criteria for 
exclusion. Participants were excluded if they had a severe mental health diagnosis. 
Participants displaying acute mental health symptoms or signs of acute intoxication at the 
time of assessment were excluded. 
 
Procedure 
Potential participants who met the criteria outlined above were identified by the team 
within their relevant service and the presence of a SMH diagnosis was ascertained from the 
service users’ clinical records by their care co-ordinators. Potential participants were then 
approached by their care co-ordinators and information concerning their cannabis usage 
within the 30 days prior was requested. If potential participants fulfilled the inclusion 
criteria, their care co-ordinators gave them a Participant Information Sheet (Appendix B). 
This informed potential participants of the purpose of the study and provided the basis for 
discussion as to whether they were interested in participating. Individuals who were 
interested in participating informed their care co-ordinator who then informed the principal 
researcher. The potential participant and their care co-ordinator met with the principal 
researcher and were given a chance to discuss the information sheet and clarify any 
questions they may have had regarding the research. It was emphasised that any 
  
information provided by them during the assessments would be held confidentially, that 
they could withdraw from the study at any time and withdrawal would in no way impact 
any current or future treatment they may receive. Participants were contacted individually 
to arrange appointments either at the location where they received their service or at their 
own accommodation, depending on their preference and an assessment of risk. At the start 
of each research interview, participants were informed that they could stop the interview, 
take a break or rearrange their appointment at any time should they wish to do so. If the 
participants felt distressed by any of the assessments, they were encouraged to express 
these concerns to the researcher. If it was the researcher’s opinion that the participant was 
either distressed or at risk at any point before, during or after the assessment, then the care 
co-ordinator was informed.   
 
Participants who agreed were asked to sign a Consent Form (Appendix C). Permission was 
given by the participant to access their notes to confirm that they met the inclusion criteria 
for the study. All participants were volunteers and received a nominal amount of £5 
voucher to reimburse them for their travel time and expenses incurred. The amount was 
assumed to be small enough not to influence response to the intervention but adequate to 
reduce non-compliance caused by any inconvenience in attending sessions.     
 
Measures  
A battery of measures was administered by the interviewer (principal researcher). The 
administration of the questionnaires involved the interviewer reading out each item to the 
participant thereby ensuring consistency and ensuring that the participant understood each 
item. In addition to the five questionnaires administered to the participants, the interviewer 
also asked each participant in both groups an open ended question “Are there any other 
reasons you use cannabis other than those you have already been asked or you have 
already stated?” and responses were recorded verbatim.  This assessment process took 
approximately 40 minutes per participant to complete.  
 
General Health Questionnaire  
Non-severe mental health was measured using The General Health Questionnaire version 
28 (GHQ-28) (Goldberg, Gater, Sartorius, Ustun, Piccinelli, Gureje & Rutter, 1997). The 
  
GHQ (28) is a measure of four common mental health domains: depression, anxiety, 
somatic symptoms and social withdrawal. The Likert scoring method is advocated for 
research as it is more sensitive to small variations. The total score for the scale ranges from 
0 to 84, a score greater than 23 is evidence of ‘caseness’ (Goldberg et al., 1997). Validity 
assessments of the scale and items were highly satisfactory (Cronbach’s alpha 0.91) 
(Appendix D) 
 
Substance use in previous 30 days 
History of substance use was gathered using ‘section B’ of the Maudsley Addiction Profile 
(MAP) (Marsden, Gossop, Stewart, Best, Farrell, Lehmann, Edwards, & Strang 1998). The 
MAP is a brief, interviewer administered questionnaire designed for treatment outcome 
research applications. The MAP assesses substances use which is broadly representative of 
the treatment seeking population in the UK. Intensity and frequency of substance use was 
assessed from the verbatim report of the amount consumed on a typical ‘using day’ in the 
past month (given by retail price, with prompting as required). With the exception of 
alcohol, the usual route(s) of administration were recorded using the following categories: 
oral, intranasal, inhalation and injection. Validity assessments of the scale and items were 
highly satisfactory (Cronbach’s alpha 0.88) (Marsden et al., 1998). (Appendix E) 
 
Cannabis dependency  
Cannabis dependency was measured using the Leeds Dependence Questionnaire (LDQ) 
which was adapted to identify dependence cannabis only rather than alcohol and other 
drugs (Raistrick, Bradshaw, Tober, Weiner, Allison, & Healey 1994). The LDQ is a 10-
item, continuous, self report measure of dependence that is not substance specific. 
Outcomes are reported on a scale from 0 (little or no dependence) to 30 (high dependence). 
There are no formal cut off points indicating presence or absence of dependence. Validity 
assessments of the scale and items were highly satisfactory (Cronbach's alpha was 0.94). 
Test-retest reliability was found to be 0.95 (Raistrick et al., 1994). (Appendix F) 
 
Motives for using cannabis 
The Drug Use Motives Measure (DUMM) was adapted by Mueser et al. (1995) from the 
Drinking Motives Measure (Cooper et al., 1992). The DUMM measures three different 
  
motives for using cannabis: coping motives, social motives and enhancement of positive 
effect and contains 15 items, with each item rated on a 4 point Likert scale. It is validated 
in the general, primary substance using and psychiatric population and has good internal 
reliability with a coefficient alpha of 0.77 (Mueser et al., 1995). The DUMM does not 
measure motives that may be specifically related to an individual’s severe mental health 
problems (for example, to medicate the symptoms of schizophrenia or to help with side-
effects from medication). To measure any SMH related motives, after completion of the 
DUMM, the SMH and non-SMH participants were asked an open-ended question “Are 
there any other reasons you use cannabis other than those you have already been asked or 
you have already stated?” and responses were recorded verbatim. (Appendix G) 
 
Expectancies from using cannabis 
The Marijuana Effect Expectancy Scale (MEEQ) was developed by Schafer et al. (1991) 
and contains 70 items describing the common effects of cannabis. Participants are asked to 
agree or disagree with each item according their current beliefs. The instrument includes 
five subscales, two measure negative effects (cognitive and behavioural impairment; global 
negative effects); three measure positive effects (relaxation and tension reduction; social 
and sexual facilitation; perceptual and cognitive enhancement). The measure is validated in 
both the general, primary substance using, and psychiatric population and has good internal 
reliability. It has a high test-retest reliabilities and good internal reliability with a 
coefficient alpha of 0.84 (Mueser et al., 1995). (Appendix H) 
 
 
 
 
 
 
 
 
 
 
 
  
The Data Analysis 
 
 
Analyses for the current study were performed using SPSS v.18 for Windows. The 
normality of distribution was assessed using the Kolmogorov- Smirnov test. Where outliers 
were present, they were removed and the analysis re-run, however the results remained the 
same. Levene’s test for homogeneity of variance was used to test the data for homogeneity. 
Multivariate analysis was conducted to explore the data in this study.  
 
In order to examine for the relationship between cannabis dependence, cannabis usage and 
the increased endorsement of coping motives, two median split procedures were 
performed. The median split technique allocates participants regardless of mental health 
status to either a high group or a low group depending upon whether they reported a score 
that was either above or below the median average. The median split was carried out for 
cannabis dependence scores (LDQ) which created high and low cannabis dependent groups 
and also for cannabis usage scores (MAP) which high and low cannabis usage groups.  
 
The data from the qualitative section where participants were asked  “Are there any other 
reasons you use cannabis other than those you have already been asked or you have 
already stated?” was recorded verbatim and these responses were then coded according to 
broad themes using a rudimentary thematic analysis. 
 
Presentation of results 
The results of the severe mental health group (SMH) group and the non-severe mental 
health group (non-SMH) are presented below and include: demographic characteristics; 
clinical characteristics (depression, anxiety, somatic symptoms and social withdrawal); 
substance use characteristics (frequency and intensity of all substances used within the 
previous 30 days, levels of cannabis dependency, cannabis motives and cannabis 
expectancies). 
 
 
 
 
  
 
Results 
 
For both the SMH group and the non-SMH group, a total of 67 and 32 potential 
participants respectively were identified who fulfilled the inclusion criteria and were 
approached by their care coordinator. Adhering to ethical procedure, the care co-ordinator, 
using the participant information sheet as guidance, discussed with the potential participant 
the purpose of the study and the implications of participation. Forty-nine potential 
participants in the SMH group and nine potential participants in the non-SMH group 
refused participation, most frequently citing a lack of interest in participating in any 
research.  
 
Demographic characteristics 
The demographic characteristics of the two samples are presented in Table 1. The SMH 
group for this study comprised 18 participants all of whom were male, with a mean age of 
39.44 years (SD = 6.74). The non – SMH group for this study comprised 20 male (87%) 
and 3 female (13%) participants, with a mean age of 30.43 years (SD = 4.97). One-way 
ANOVA between the two samples showed significant differences in age (F(1,39) = 24.25, 
P<0.01) with an older mean age in the SMH group compared to the non-SMH group. The 
SMH and non-SMH groups did not differ on gender or ethnicity.  
 
Mental health characteristics 
On measures of general mental health, the groups did not differ on depression, anxiety, 
somatic symptoms or social withdrawal, suggesting the groups were comparable. 
Information was gathered on the severe mental health diagnoses of both groups by 
accessing their clinical file (electronic and paper). Of the participants in the SMH group, 
50% were diagnosed with paranoid schizophrenia, 44% were diagnosed with schizophrenia 
and 6% were diagnosed with schizoaffective disorder. None of the participants in the non-
SMH group were diagnosed with severe mental health problems. 
 
 
 
  
Table 1: Demographic and mental health characteristics of the severe mental health and 
non-severe mental health groups.   
 
Measure Non SMH Group 
N=23 
SMH Group 
n=18 
 
P value 
Age 1 (years) 
Range (years) 
 
30.43 (4.97)  
19 
39.44  (6.74) 
25 
F(1,39) = 24.25 p<0.01 
Gender 
Male 
Female 
 
20 
3 
 
18 
0 
 
- 
- 
 
Ethnicity 
White UK 
Asian 
White/Black 
Caribbean 
Black Caribbean 
 
18 (78.3%) 
1 (4.3%) 
2 (8.7%) 
 
2 (8.7%) 
 
 
13 (72.2%) 
1 (5.6%) 
1 (5.6%) 
 
2 (11.1%) 
 
- 
- 
- 
 
- 
Mental Health 
Diagnosis 
 
Schizophrenia 
Paranoid - 
Schizophrenia 
Schizoaffective 
 
 
 
 
- 
- 
 
- 
 
 
 
8 (44%)     
9 (50%)  
 
1 (6%) 
 
 
 
- 
- 
 
- 
General Health 
Questionnaire  
 
Anxiety1  
Depression1 
Somatic1 
Social Withdrawal1 
Total 1 
 
 
 
 
6.17 (3.75) 
2.65 (2.88) 
5.48  (4.05) 
5.87 (2.71) 
20.13 (9.92) 
 
 
 
4.28 (3.90) 
3.50 (5.27) 
5.56 (3.39) 
6.56 (2.45) 
19.89 (11.14) 
 
 
 
 
F(1,39) = 2.48 n.s 
F(1,39) = 0.43 n.s 
F(1,39) = 0.00 n.s 
F(1,39) = 0.69 n.s 
F(1,39) = 0.00 n.s 
1 Mean and (Standard deviation) 
 
 
 
 
 
 
 
 
 
 
  
Substance use characteristics  
 
Substance use in last 30 days  
The SMH and non-SMH groups did not differ significantly on substances used in the 
previous 30 days, suggesting the substance use behaviour of the two groups was 
comparable. A number of non-statistically different variations in substance use included: 
the SMH group reported consuming more cannabis per day but using for fewer days. 
Whilst both groups used alcohol for similar numbers of days, the SMH group consumed 
more alcohol per day. The non-SMH group used heroin and crack on more days and more 
per day compared to the SMH group. Cocaine and amphetamines were used by a small 
minority: only two participants used cocaine in each group; only one participant in the 
SMH group used amphetamines. The minority of participants who used cocaine and 
amphetamines tended to use large quantities. These outliers were not removed, but instead 
are reflected in standard deviation scores reported in Table 2 (below). None of the 
participants in either group reported using any other illicit substance in the previous 30 
days.   
 
Cannabis dependence  
The SMH group and the non –SMH group did not differ on measures of cannabis 
dependency suggesting the two groups were comparable. In interpreting the clinical 
severity of these results, the LDQ does not employ cut-off scores for dependence. 
Comparing the mean scores (9.39 and 7.57) in the present study with the mean scores 
(18.65) reported in a study of 300 primarily cocaine and opiate users (Kelly, Magill, 
Slaymaker & Kahler, 2010) suggests that neither the SMH nor the non SMH group were 
likely to have been considered to be severely dependent upon cannabis.  
 
Cannabis use history 
The SMH group and the non –SMH group did not differ on measures of age when cannabis 
was first used and when cannabis was first used regularly. However the SMH group had 
used cannabis for a longer duration compared to the non-SMH group (F(1,39) = 24.25, 
P<0.01). This difference is considered to reflect the increased mean age of the SMH group 
compared to the non-SMH group. 
  
Table 2: Table showing measures of current substance use, cannabis dependence and 
cannabis use history. 
 
Measure Non SMH Group 
N=23 
SMH Group 
n=18 
 
P value 
Substance use in 
prior 30 days 
(money spent) 
 
Cannabis1 (£) 
Range  
Alcohol1 (units) 
Range  
Heroin1  (£) 
Range 
Crack Cocaine 1 (£) 
Range 
Cocaine 1 (£) 
Range 
Amphetamines 1 (£) 
Range  
 
 
 
 
 
146.86   (160.12) 
446 
132.91   (147.27) 
600 
97.39     (203.00) 
900 
77.39     (146.94) 
600 
10.43     (36.61) 
160 
0.0 (0.00) 
0 
 
 
 
 
185.50    (218.89) 
742 
154.11    (205.74) 
750 
21.66      (52.04) 
200 
46.66      (146.00) 
600 
6.66      (28.28) 
120 
66.66 (282.84) 
1200 
 
 
 
 
F(1,39) = 0.42  n.s 
 
F(1,39) = 0.14  n.s 
 
F(1,39) = 2.37  n.s 
 
F(1,39) = 0.44  n.s 
 
F(1,39) = 0.89  n.s 
 
F(1,39) = 1.28  n.s 
 
Leeds Dependency 
Questionnaire  
 
Mean1 
 
 
 
 
7.57 (5.28) 
 
 
 
 
9.39 (6.86)  
 
 
 
 
F(1,39) = 0.92 n.s 
Cannabis use history 
 
Age first used 
cannabis1 
 
Age started to use 
regularly1 
 
 
 
14.17 (3.39) 
 
 
17.65 (6.05) 
 
 
 
16.17 (3.79) 
 
 
18.44 (4.91) 
 
 
 
 
 
F(1,39) = 3.14 n.s. 
 
 
F(1,39) = 0.20 n.s. 
 
Duration using 
cannabis 
 
Years using cannabis1 
 
Years using cannabis 
regularly1 
 
 
 
 
16.29 (4.80) 
 
12.78 (6.61) 
 
 
 
 
23.27 (7.4) 
 
21.00 (9.00) 
 
 
 
 
F(1,39) = 13.46 p<0.01 
 
F(1,39) = 11.36  p<0.01 
 
1 Mean and (Standard deviation) 
 
 
 
 
 
  
 
Hypothesis one - motives and expectancies from using cannabis  
The primary hypothesis was that there would be no difference between the SMH and the 
non-SMH group on motives for using cannabis or difference on the endorsement of 
negative and positive expectancies from using cannabis.  
 
Motives 
A one-way between groups ANOVA was conducted to explore the impact of group 
membership on the endorsement of enhancement, coping and social motives, as measured 
by the DUMM. There was not a statistically significant difference at the p <0.5 level in 
enhancement, coping or social motives scores for the two groups. This indicates that there 
were no significant differences in motives for using cannabis between the SMH and the 
non-SMH group. 
 
Expectancies 
A one way between groups ANOVA was conducted to explore the impact of group 
membership on positive, negative and neutral expectancies. The two groups differed on 
one of the three positive expectancies: the SMH group expected greater ‘social and sexual 
facilitation’ (F(1,39) = 5.33 P<0.05). The two groups differed on one of the two negative 
expectancies: the SMH group expected lesser ‘cognitive and behavioural impairment 
(F(1,39) = 5.23 P<0.05). In summary, the SMH group expected increased ‘social and sexual 
facilitation’ from using cannabis and reduced ‘cognitive and behavioural impairment’ from 
using cannabis compared to the non-SMH group. 
 
 
 
 
 
 
 
 
 
  
Table 3: Comparisons of motives and expectancies of the severe mental health group and 
the non-severe mental health group. 
 
Measure Non SMH Group 
N=23 
SMH Group 
n=18 
 
P value 
Motives for cannabis 
use  
 
Enhancement1 
Social Reasons1 
Coping1 
 
 
 
12.17 (3.20) 
10.70 (2.47) 
12.09 (4.17) 
 
 
 
12.67 (2.99) 
11.56 (3.89) 
11.28 (4.24) 
         
 
 
 
F(1,39) = 0.25 n.s 
F(1,39) = 0.74 n.s 
F(1,39) = 0.37 n.s 
 
Cannabis 
expectancies 
 
Relaxation /tension 
reduction1   
Social /sexual 
facilitation1   
Perceptual /cognitive 
enhancement1  
Global negative 
effects1 
Cognitive behavioural 
impairment1  
 
 
 
 
 
6.08 (2.23) 
 
3.91 (2.60) 
 
4.78 (2.57) 
 
2.86 (2.09) 
 
8.43 (2.92) 
 
 
 
 
6.01 (1.78) 
 
5.72 (2.32) 
 
5.38 (2.40) 
 
3.16 (2.70) 
 
6.00 (3.89) 
 
 
 
 
F(1,39) = 0.01 n.s 
 
F(1,39) = 5.33 p<0.05 
 
F(1,39) = 0.59 n.s 
 
F(1,39) = 0.15 n.s 
 
F(1,39) = 5.23 p<0.05 
 
1 Mean and Standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Hypothesis Two - cannabis dependency and cannabis usage  
The secondary hypothesis was that regardless of mental health status, participants who 
were categorised into high cannabis usage and participants categorised into high cannabis 
dependence would endorse more coping and enhancement motives, more positive 
expectancies and less negative expectancies compared to their low cannabis usage and low 
cannabis dependent counterparts.  
 
Motives and cannabis dependency  
A two way between groups ANOVA was conducted to establish whether there was a 
difference between cannabis dependency, mental health status and coping, enhancement 
and social motives between the two groups. A significant main effect was observed for 
coping (f1,37 = 5.08; p<0.05) and enhancement (f1,37 = 13.66; p<0.01) and cannabis 
dependency. No other significant main or interaction effects were observed. In summary, 
the high dependent group endorsed more coping and enhancement motives than the low 
dependent group. 
 
Motives and cannabis usage  
A two way between groups ANOVA was conducted to establish whether there was a 
difference between cannabis usage, mental health status and coping, enhancement and 
social motives in the two groups. A significant main effect was observed for coping (f1,37 
= 4.88; p<0.05) and cannabis usage status. The value for enhancement motive approached 
being significant (p value of p=0.07). No other main or interaction effects were reported. In 
summary, the high usage group endorsed more coping motives compared to the low usage 
group. 
 
Expectancies and cannabis dependency 
A two way between groups ANOVA was conducted to establish whether there was a 
difference between cannabis dependence, mental health status and cannabis expectancies 
in the two groups. Of the positive expectancies, a significant interaction effect for ‘tension 
reduction and relaxation’, severe mental health status and dependency group was observed 
(F3,37 = 4.60; p <0.05). No other main or interaction effects were reported. In summary, 
increased dependence was associated with reduced expectations of ‘tension reduction and 
  
relaxation’ amongst SMH participants. The opposite was observed amongst the non-SMH 
group, increased dependency was associated with increased expectations of ‘tension 
reduction and relaxation’.  
 
Of the negative expectancies, a significant interaction effect for ‘cognitive behavioural 
impairment’, mental health status and dependency group was observed (F3,37 = 12.51; p 
<0.01). No other main or interaction effects were reported. In summary, amongst the SMH 
group, increased dependency was associated with increased expectations of ‘cognitive and 
behavioural impairment’. The opposite was observed amongst the non-SMH group, 
increased dependency was associated with decreased expectations of ‘cognitive and 
behavioural impairment’. 
 
Expectancies and cannabis usage 
A two way between groups analysis of variance was conducted to establish whether there 
was a difference between cannabis usage status, mental health status and cannabis 
expectancies. Of the positive expectancies, a significant interaction effect for ‘tension 
reduction/relaxation’, mental health status and cannabis usage status was observed (F3,37 
= 6.27; p <0.05). Therefore amongst the SMH group, increased cannabis usage was 
associated with reduced expectations of ‘tension reduction and relaxation’. The opposite 
was observed amongst the non-SMH group: increased cannabis usage was associated with 
increased expectations of ‘relaxation and tension reduction’. A significant main effect was 
observed for ‘social and sexual facilitation’ and mental health status (F3,37 = 5.55; p 
<0.05). Therefore irrespective of cannabis usage status, significantly more SMH 
participants expected ‘social and sexual facilitation effects’ compared to the non-SMH 
group. Of the two negative expectancies, a significant main effect was observed for 
‘cognitive/behavioural impairment’ and cannabis usage group. (F3,37 = 4.85 ; p <0.05). 
Regardless of mental health status, the higher usage group expected significantly less 
‘cognitive behavioural impairment’ from using cannabis compared to the low usage group. 
No other main or interaction effects were reported.  
 
 
 
  
Qualitative results 
The DUMM does not assess for motives related to SMH problems, therefore after 
administering the DUMM a qualitative question was asked to all participants “Are there 
any other reasons you use cannabis other than those you have already been asked or you 
have already stated?” Nineteen responses from the SMH group were recorded verbatim. 
These responses were then coded according to broad themes using a rudimentary thematic 
analysis. Five broad themes were identified. These are outlined below together with the 
participants’ responses. 
  
Theme 1: Motives to cope with SMH related problems  
Two participants reported using cannabis to reduce auditory hallucinations: “I use cannabis 
to reduce the voices I hear” and “it calms the voices”. One participant reported using 
cannabis to compensate for the side effects of SMH related medication, “I use it to speed 
up my thinking because the medication slows my thinking down”.  
 
Theme 2: Motives to increase cognitive or behavioural performance 
Three responses reported using cannabis to help improve cognitive performance: “I use it 
to help me concentrate when I am on the computer…. playing games”; “Smoking focuses 
my mind when I am doing something” and “I use cannabis because I find it easier to 
concentrate on things when I smoke”. One participant’s response concerned using cannabis 
to increase their motivation. “Cannabis increases my motivation to do things as I can’t do 
anything until I have had a smoke”.  
 
Theme 3: Coping motives  
Two participants’ responses which were categorised as motives to cope with negative 
affect: “it stops me from getting bored” and “cannabis helps me sleep”. One participant 
reported using cannabis “to help with ‘coming down’ from amphetamines”.  
 
Theme 4: Enhancement motives 
Two responses were classed as motives related to enhancement of positive effect these 
were: “cannabis makes the music I listen to sound better” and “cannabis enhances the high 
from the vodka that I drink”.  
  
Theme 5: Attributions 
Six responses were categorised as attributions for using cannabis use rather than motives 
for using cannabis, these were “It’s just a habit, because I’m addicted, because it’s 
available so I have it”. Attributions have been distinguished from motives within the 
alcohol literature (Young & Knight, 1989). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Discussion  
 
The present study was the first to use standardised measures to compare cannabis motives 
and expectancies amongst two groups, one with severe mental health problems and one 
without. The two groups reported comparable levels of cannabis use, cannabis dependence 
and non-severe mental health. The two groups did differ significantly on mean age and 
hence were not comparable on this characteristic.  
 
Primary hypothesis 
The primary hypothesis was that the SMH group and non-SMH group would not differ on 
the motives and expectancies endorsed.  
 
Motives 
On quantitative measures of the motives or proximal reasons for using cannabis, the SMH 
and non-SMH group did not differ significantly and therefore the primary hypothesis was 
partially supported. The scores reported on the DUMM by both groups are considered 
comparable to the scores reported on the DUMM amongst individuals with SMH and 
recent drug use (14.69 positive enhancement; 12.37 for coping with negative emotions 
and11.56 for social motives) (Mueser et al.,1995). The outcome of the present study did 
not support the results of Schaub et al. (2008) or Green et al. (2004) who found that 
significantly more SMH participants endorsed ‘boredom’ as a reason for smoking cannabis 
compared to non-SMH participants. Whilst the motives measure used in the present study 
(DUMM) does not include an item that specifically addresses ‘boredom’ as a motive for 
using cannabis, in the qualitative self-report component of the present study, the motive of 
‘boredom’ was endorsed by a very small minority of participants (one participant in the 
SMH group and one participant in the non-SMH group). Additional outcomes from the 
qualitative data indicated that a small minority of participants with SMH problems (3 out 
of 18 participants) reported motives for using cannabis that were related to either their 
SMH symptoms or side effects of their SMH medications. This finding replicated 
outcomes reported in previous studies evaluating motives amongst individuals with SMH 
problems which used a qualitative methodology (for example: Fowler et al.,1998; Dixon et 
al., 1990; Green et al., 2004). 
  
The clinical implications of the findings on motives from the present study are that given 
motives do not differ significantly between SMH and non-SMH groups, then the treatment 
approaches that have been developed for non-severe mental health substance users which 
focus on the motivational underpinnings of substance use behaviour (for example, relapse 
prevention and motivational interviewing: Marlatt & Gordon, 1985; Miller & Rollnick, 
2002) may also be of benefit to people with severe mental health problems. The clinician, 
in their assessment of the service user’s motives for using cannabis, should be vigilant for a 
small minority that may use cannabis for SMH related reasons. Clinicians should address 
these motives, thus reducing the need for patients to use cannabis, and therefore reducing 
the risk of relapse. The application of such interventions to individuals with SMH 
problems may require adaption to take account of any cognitive or affective difficulties 
they may experience (Barrowclough et al., 2006). 
 
Expectancies  
The outcomes from the measure of cannabis expectancies (distal beliefs about the effects 
that might be experienced from using cannabis), indicated that the SMH group were more 
likely to expect cannabis to be ‘socially and sexually facilitative’. These expectancies were 
prevalent amongst all SMH participants regardless of cannabis use and dependency status 
and therefore the primary hypothesis was not fully supported. In understanding this 
finding, expectancies can be derived from a combination of environmental and cultural 
influences, interactions with peers and previous experiences of use (Schafer & Brown, 
1991). It may be that individuals with SMH are exposed to environments where cannabis is 
viewed as being socially and sexually facilitative and these beliefs are then internalised. 
Evidence suggests that individuals with schizophrenia have reduced opportunities for 
social activity and may experience a loss of social status resulting from the stigma of 
having a SMH problem (Birchwood, Trower, Brunet, Gilbert, Iqbal, Jackson, 2007).  
Cannabis use may represent a non-stigmatising route through which increased social 
interaction and social status may be achieved, with a lack of availability of more adaptive 
approaches. It is hypothesised that beliefs about cannabis may develop through exposure to 
other people who may hold beliefs that cannabis is socially and sexually facilitative via 
cannabis-using social networks or ward environments. This exposure may occur either 
  
before or after the onset of SMH problems. Over time, an individual may also form the 
belief that cannabis is socially and sexually facilitative.   
 
The SMH group endorsed fewer expectancies of ‘cognitive/behavioural impairment’ 
compared to the non-SMH group. In understanding this finding, evidence suggests that 
individuals with SMH problems frequently experience a number of cognitive deficits (for 
example, memory problems, attention deficits, difficulties in abstract thought, executive 
functioning) as well as behavioural impairments (for example, apathy and negative SMH 
symptoms Berenbaum, Kerns, Vernon, & Gomez, 2008). It is hypothesised that existing 
cognitive and behavioural impairment may make any additional cognitive and behavioural 
impairment, as a result of smoking cannabis, increasingly difficult to detect. Through 
repeated exposure to cannabis-using SMH peers who may hold beliefs that cannabis does 
not cause ‘cognitive/behavioural impairment’. I would suggest that over time, an 
individual exposed to this environment may then also less inclined to expect cannabis to be 
cognitive or behavioural impairing.  
  
In terms of the clinical implications of these findings, individuals are more likely to use a 
substance when they hold overly positive expectancies about its effect (Aarons et al., 
2001). Overly positive expectancies about the social and sexual facilitation and cognitive 
and behavioural impairment from using cannabis may be counterbalanced through 
interventions such as cognitive restructuring (Beck, 1975) which aims to replace counter-
factual beliefs with more adaptive evidence-based beliefs. The results of a study by Green, 
Kavanagh and Young (2007) indicate that when individuals with psychosis become more 
aware of the negative outcomes of cannabis they are able to reduce the frequency of their 
cannabis use. In conclusion, motives for cannabis use do not differ between the SMH and 
non-SMH group, however expectations do differ as the SMH group expect more ‘social 
and sexual facilitation’ and expect less ‘cognitive behavioural impairment’ from using 
cannabis, consequently the primary hypothesis is not fully supported.  
 
 
 
 
  
Secondary hypothesis 
 
The secondary hypothesis that participants categorised as either more cannabis dependent, 
or as higher users of cannabis would endorse more coping and enhancement motives, more 
positive expectancies, and fewer negative expectancies compared to participants that are 
less dependent or low cannabis usage.  
 
Motives 
The findings partially supported this hypothesis. Regardless of mental health status, high 
cannabis-dependent participants endorsed both ‘coping’ and ‘enhancement’ motives 
significantly more often than the low cannabis dependent group. The high cannabis usage 
group endorsed more ‘coping’ motives compared to the low usage group (the outcome for 
enhancement approached being significant). These outcomes suggest that cannabis use is 
not differentially rooted in the regulation of negative and positive emotions amongst 
individuals with and without SMH problems but is differentially rooted in the regulation of 
negative and positive emotions amongst individuals with higher levels of cannabis 
dependency and usage. This finding lends credence to a motivational perspective (Cox & 
Klinger, 1988) and highlights its utility in understanding problematic cannabis use amongst 
individuals with SMH problems. The present finding supports other research carried out 
amongst the SMH population. Mueser et al. (1995) and Spencer et al. (2002), both found 
that amongst participants with SMH, more problematic use was associated with both 
increased ‘coping’ and ‘enhancement’ motives.  
 
The clinical implications of the present study suggest that motives associated with more 
problematic cannabis use appear to be related to coping with negative affect (i.e. the relief 
of dysphoria/ distress) and enhancement (i.e. the pursuit of pleasurable activities). 
Interventions aimed at reducing sources of dysphoria / distress directly and/or developing 
more adaptive ways of coping with these stressors may be helpful for reducing coping 
motives. Treatments aimed at developing more adaptive ways of obtaining pleasure, 
reducing the limitations for obtaining pleasure, which may involve facilitating less 
restricted lifestyles or addressing circumstances associated with marginalisation 
(Birchwood et al., 2007) may be helpful in reducing enhancement motives. The reduction 
  
of such motives may reduce the inclination to use cannabis which may then reduce the risk 
of relapse.  
 
Expectancies  
It was hypothesised that more problematic cannabis use would be associated with 
increased positive expectancies and decreased negative expectancies about the effects of 
cannabis.  
 
This hypothesis was not supported. Amongst the SMH group, there was no difference 
between problematic and non-problematic cannabis users in endorsement of ‘perceptual 
and cognitive enhancement’, ‘social and sexual facilitation’ (as discussed above) and 
‘global negative effects’. However, two findings amongst the SMH group (but not the non-
SMH group) were contrary to the hypothesis. First, high dependent cannabis users 
expected significantly less ‘tension reduction and relaxation’ and more ‘cognitive and 
behavioural impairment’ compared to non-problematic cannabis users. A study by Hides, 
Kavanagh, Dawe & Young, (2009) using the Cannabis Expectancy Questionnaire (Young 
& Kavanagh, 1997), also found that amongst SMH participants, more cannabis dependent 
participants reported more negative expectancies compared to less dependent participants. 
Mueser et al. (1995) did not report this finding amongst cannabis users compared to non 
cannabis users both with SMH problems and this finding is contrary to the research 
amongst the general substance using population. The reasons for this discrepancy are 
unclear, although it is recognised that opposing stimulation and sedation effects from 
cannabis have been reported within a single occasion or between occasions of use and may 
be accounted for the effects from cannabis being multi-dimensional (Block, Erwin, 
Farinpour & Braverman, 1998). The multi-dimensional effects of cannabis were apparent 
when administering the MEEQ; participants frequently reported that the effects of cannabis 
had different effects at different times.  
 
In summary, the possible multi-dimensional effects of cannabis may contribute to the 
variation in expectancies amongst SMH and non-SMH problematic cannabis users, 
although further research is required to corroborate and understand this finding. However, 
what appears to be a stable and consistent pattern is that ‘social and sexual facilitation’ is 
  
endorsed significantly more by individuals with SMH problems regardless of cannabis use 
status. 
 
 
Limitations of the present study  
One limitation is the small sample size used. The study aimed to collect 25 participants for 
each group but was only successful in recruiting 18 and 23 participants. This was 
considered to reflect the issues concerning engagement experienced within the Assertive 
Outreach Teams. It was considered an oversight to have not recorded prescribed 
medication as it is conceivable that these may have impacted upon participants’ cannabis 
use or reasons for using and may have differed between the two groups. It is suggested by 
Addington et al. (1997) that current use of cannabis to help with SMH problems may 
depend on whether participants were currently symptomatic or not. The study excluded 
individuals who were acutely symptomatic. The current study does not therefore represent 
motives or expectancies for cannabis use amongst individuals who are acutely 
symptomatic.  
 
Future Work 
Suggestions for future work would first be to think about a strategy to increase participant 
numbers. My experience of the recruitment of individuals with SMH problems was 
complicated by the issue that I was not based in any of the Assertive Outreach Teams. If a 
researcher was based in one or more of these teams this may facilitate the recruitment of a 
larger number if participants. Second, future work could explore how, if at all, the 
differences in age between the SMH and non-SMH group may have influenced the 
outcomes from the present study. Therefore I would suggest that any future study could 
recruit participants, with and without SMH problems, but of a comparable age. This would 
lend support to the current finding. The above two issues could possibly be remedied 
through recruiting SMH participants from Early Intervention Services. Early Intervention 
Services are services that typically help people when they experience a first episode of 
psychosis. First, Early Intervention service users typically tend to be much younger than 
Assertive Outreach service users, as first episodes of psychosis typically occur between the 
age of 18 to 30. Second, Early Intervention service users may typically be less hard to 
  
engage and recruit compared to Assertive Outreach service users. This would therefore 
facilitate the recruitment of a greater number of participants. A third area that I suggest for 
future work follows on from the hypothesis in the present study that expectancies of 
cannabis being socially and sexually facilitative amongst individuals with SMH problems 
may stem from cannabis using social networks or the influences from ward environments. 
A research study might compare the expectations and motives for using cannabis between 
participants with SMH problems who do and do not use cannabis and have and have not 
been exposed to cannabis using social networks / environments. This may contribute to the 
prevalence of any correlation between cannabis use and exposure to cannabis using 
environments and people.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Conclusion 
 
 
The central finding to emerge from the present study was that individuals with SMH 
problems do not differ from individuals without SMH problems on their motives for using 
cannabis: they use for coping, enhancement and social reasons. However, individuals with 
SMH problems differ in that they expect cannabis to be more ‘socially and sexually 
facilitative’. This suggests that treatments developed for individuals without SMH 
problems which are underpinned by understanding the motives and the expectancies from 
the effects of using a substance may be effective for individuals with SMH problems. The 
finding from the qualitative component of the study indicated that only a small minority of 
individuals with SMH problems used cannabis to help with their symptoms of their SMH 
problem or side-effects of prescribed medication. The second main finding indicated that 
regardless of mental health status, participants who used cannabis more problematically 
endorsed more coping and enhancement motives. Interventions aimed at reducing sources 
of distress, developing more adaptive ways of coping, together with treatments aimed at 
reducing the limitations for obtaining pleasure may be helpful in reducing enhancement 
and coping motives amongst more problematic cannabis users with SMH problems.  
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    Public Domain Briefing Document 
 
Cannabis use amongst individuals with severe mental health problems: Reasons for 
use and motivational based interventions 
 
This thesis was submitted as part of the Doctorate in Clinical Psychology at the School of 
Psychology, University of Birmingham. This document will describe Volume I that 
comprises two parts: a review of the literature and a research or empirical study. 
 
Literature review 
The first part of the review discusses motivational interviewing that has been shown to be 
effective in reducing a number of problematic behaviours including alcohol and substance 
use in the general population. The review then evaluates the effectiveness of a number 
studies that incorporate motivational interviewing into the intervention amongst 
participants with severe mental health problems, such as schizophrenia or major 
depression. These studies aim to either reduce unhealthy behaviours such as alcohol or 
substance use, or increase healthy behaviours such as adherence to prescribed medication 
or attendance to the service where they receive treatment. The review found that such 
approaches were helpful in reducing substance use, most notably alcohol and tobacco use 
but there was less support for the approaches reducing cannabis use. The review found that 
motivational based interventions were also effective at increasing the attendance of 
individuals with severe mental health problems to appropriate services where they receive 
treatment. However, the evidence was less consistent when the intervention aimed to 
increase adherence to prescribed medication. Overall, the positive effect from the 
interventions diminished over time. Consequently the intervention may have to be repeated 
at regular intervals to maintain an individuals’ motivation to change their behaviour. 
Additionally, a number of the studies indicated that a motivational based approach may not 
be as helpful for individuals where their levels of motivation for changing behaviour are 
already initially high and for such individuals other interventions such as psycho-education 
may be equally as effective.  
 
 
  
Empirical Paper   
 
Background: Individuals with severe mental health problems (a diagnosis on the 
schizophrenia spectrum) often continue to use cannabis despite the issue that continued use 
can often make the symptoms of their illness worse. A model of alcohol use that has 
received widespread support indicated that the reasons for using alcohol can be divided 
into two; with the first related to the beliefs that an individual has about the effects of using 
alcohol and secondly the present motives that drive the individual to continue to use 
alcohol. The current study applied this framework to understand why some people with 
severe mental health problems continue to use cannabis by comparing the beliefs and 
motives for using cannabis between individuals who had a severe mental health problem 
with individuals who did not.  
 
Method: Eighteen participants with severe mental health problems and twenty three 
participants without severe mental health problems who had used cannabis recently were 
asked to meet with the researcher and complete a series of questionnaires. The 
questionnaires asked them about their recent drug and alcohol use, dependence on 
cannabis, general health and their distal beliefs and proximal motives for using cannabis. 
The outcomes of these questionnaires were compared between the two groups. 
 
Results: It was found that the group with severe mental health problems did not differ in 
their proximal motives for using cannabis when compared to the group without mental 
health problems, with both groups citing reasons for use associated with socialising, coping 
with difficult emotions and for enjoyment or pleasure reasons. However, the group with 
severe mental health problems differed in that they believed or expected that using 
cannabis would be socially and sexually helpful. A further finding was that regardless of 
whether a participant had a severe mental health problem or not, if a participant was 
categorised as using cannabis more problematically then they were more likely to use 
cannabis for reasons associated with coping with negative emotions and for reasons 
associated with enjoyment or pleasure.       
 
 
  
Conclusions: The findings from the study indicated that participants with a severe mental 
health problem did not have different proximal motives for using cannabis compared to 
individuals without severe mental health problems. Therefore interventions developed 
amongst the general substance using population that aim to understand these motives for 
using a substance and have been demonstrated to be effective in reducing substance use 
(for example motivational interviewing or harm reduction), may also be effective amongst 
individuals with severe mental health problems. The finding that participants with severe 
mental health problems believe or expect cannabis to enhance their social or sexual 
performance may mean that interventions which aim to challenge unhelpful or counter-
factual beliefs are helpful. Alternatively, facilitating more adaptive ways to achieve social 
interaction for individuals with severe mental health problems may be helpful. 
 
 
 
 
